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Autism spectrum disorders (ASD) are a group of related neurodevelopmental diseases displaying 
significant genetic and phenotypic heterogeneity. Despite recent progress in ASD genetics, the 
nature of phenotypic heterogeneity across probands is not well understood. Notably, likely gene-
disrupting (LGD) de novo mutations affecting the same gene often result in substantially 
different ASD phenotypes. We find that truncating mutations in a gene can result in a range of 
relatively mild decreases (15-30%) in gene expression due to nonsense-mediated decay (NMD), 
and show that more severe autism phenotypes are associated with greater decreases in 
expression. We also find that each gene with recurrent ASD mutations can be described by a 
parameter, phenotype dosage sensitivity (PDS), which characterizes the relationship between 
changes in a gene’s dosage and changes in a given phenotype. Using simple linear models, we 
show that changes in gene dosage account for a substantial fraction of phenotypic variability in 
ASD. We further observe that LGD mutations affecting the same exon frequently lead to 
strikingly similar phenotypes in unrelated ASD probands. These patterns are observed for two 
independent proband cohorts and multiple important ASD-associated phenotypes. The observed 
phenotypic similarities are likely mediated by similar changes in gene dosage and similar 
perturbations to the relative expression of splicing isoforms. We also identify patterns of 
developmental and cell type-specific expression that additionally contribute to the variability of 
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Recent advances in neuropsychiatric genetics [1-4] and, specifically, in the study of 
autism spectrum disorders (ASD) [5-8] have led to the identification of multiple genes and 
specific cellular processes that are affected in these diseases [5, 6, 8-10]. However, phenotypes 
usually associated with ASD vary considerably across autism probands [11-14], and the nature of 
this phenotypic heterogeneity is not well understood [15, 16]. Despite the complex genetic 
architecture of ASD [17-22], a subset of cases from simplex families, i.e. families with only a 
single affected child among siblings, are known to be strongly affected by de novo mutations 
with severe deleterious effects [8, 23, 24]. Interestingly, despite having relatively simpler genetic 
architecture, simplex autism cohorts often display as much phenotypic heterogeneity as more 
general cohorts [25-27]. This provides an opportunity for an in-depth exploration of the etiology 
of the autism phenotypic heterogeneity, at least for these cohorts, using accumulated phenotypic 
and genetic data. In the presented work, we performed such an investigation of genotype-to-
phenotype relationships in ASD. 
 
1.1 Thesis overview 
In the presented studies, we investigated the effects of de novo LGD mutations on 
cognitive and other important ASD-related phenotypes, including adaptive behavior, motor 
skills, communication, and coordination. Initial analyses of LGD mutations both in large-scale 
sequenced human populations and in two independent simplex ASD cohorts [28, 29] revealed 
quantitative relationships between changes in gene dosage induced by nonsense-mediated decay 
(NMD) and the effects of LGD mutations on cognitive and behavioral phenotypes. We then 
explored simple linear models relating losses of gene dosage to the severity of ASD phenotypes. 
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To that end, we introduced a genetic parameter, the phenotype dosage sensitivity (PDS), 
quantifying the change in a specific autism phenotype per unit change in a target gene’s dosage. 
These analyses showed that changes in dosage can explain a significant fraction (~40%) of the 
variability of autism phenotypes in specific probands. We further investigated whether, due to 
consistent patterns of exon usage, LGD mutations in the same exon would result in (1) similar 
dosage changes in the target genes and, consequently, (2) in similar autism phenotypes. We 
demonstrated that truncating mutations in the same exon often led to similar phenotypes in 
unrelated ASD probands. We observe consistent patterns of phenotypic heterogeneity for 
multiple important autism phenotypes and validated these findings in independent ASD cohorts. 
Finally, we investigated associations between phenotype severity and the developmental 
expression of exons as well as the expression of ASD-associated genes in neuronal cell types. 
 
1.2 Background 
Epidemiology and genetics of ASD 
Autism spectrum disorders (ASD) are a group of psychiatric disorders characterized by 
two core phenotypes: (1) the impairment of social interactions and communication and (2) 
patterns of repetitive behaviors and restricted interests [30]. The prevalence of ASDs is estimated 
to be 1 in 59 (~1.5%) [31], with a substantial genetic risk component (estimated heritability ~40-
90%) [17, 32, 33]. Notably, ASD presents two distinct patterns of inheritance [17, 34], namely 
multiplex autism, in which multiple individuals in a family are affected through the transmission 
of inherited variants, and simplex (or sporadic) autism, in which only a single member of a 
family is affected. 
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Recent progress in ASD genetics suggests that diverse genetic insults, including copy 
number variation [7, 35], rare and de novo single nucleotide variants [36], regulatory variants 
[37], and common inherited polymorphisms [17, 19, 38], contribute to these disorders. Recent 
large-scale sequencing studies in simplex families have demonstrated strong enrichment of de 
novo mutations among probands. Highly damaging, so-called likely gene-disrupting (LGD) de 
novo mutations (including nonsense, frameshift, and splice-site mutations), in particular, are 
estimated to contribute to ~30% of simplex cases [8, 39]. Of an estimated 500-1000 ASD risk 
genes susceptible to LGD mutations, more than 100 genes have been implicated with genome-
wide significance [9, 40]. 
Given the diversity of risk genes targeted by LGD mutations (Figure 0.1), ongoing 
studies have characterized the functional properties of ASD-associated genes [6, 12, 41], for 
example in terms of their molecular pathways, positions on biological networks, and spatial and 
temporal expression patterns. Such studies suggest that important cellular functions – including 
cytoskeletal and axonal projections, synapse formation, ion channel signaling, chromatin 
modification [35], and the developmental regulation of transcription – are likely perturbed by 
mutations in ASD [40, 41]. Notably, investigations of the spatial expression patterns of ASD 
genes have shown nearly ubiquitous expression throughout the brain [41] (Figure 0.2), and 




Figure 0.1 Diversity of ASD risk genes affected by de novo LGDs and CNVs. Each numbered 
band represents a human chromosome. Points represent the locations of de novo LGD mutations and 
CNVs observed in simplex ASD populations. Lines between points and chromosomes indicate the 
chromosomal location of each genetic insult. Colors represent different classes of mutations: nonsense 




Figure 0.2 Expression bias towards regions of the human brain. Each bar represents the 
expression bias, calculated as the difference between the median expression levels ASD and control 
genes, for nine anatomical regions of the human brain. Bars are ordered alphabetically along the x-axis. 
The y-axis represents the observed expression bias. As the control gene set, we considered genes with 
nonsynonymous mutations in unaffected siblings in the SSC cohort. Error bars represent SEM estimated 
by statistical bootstrapping. 
 These findings constitute important steps towards understanding the cellular and 
molecular effects of mutations underlying ASD. However, the phenotypic consequences of 
perturbations to these pathways, for example at the levels of neuronal circuit dynamics [44, 45] 
and complex cognitive and behavioral phenotypes [26, 46, 47], are not well understood. 
 
Phenotypic diversity in ASD 
Connecting genetic insults mechanistically to complex cognitive and behavioral 
phenotypes remains a key challenge in the study of psychiatric disease. In autism, for example, 
affected individuals exhibit substantial heterogeneity in both autistic and autism-associated traits. 
Investigations of the nature of such heterogeneity, however, are challenging due to the relatively 
complex genetic architecture of ASDs. To wit, many types of genetic insults (i.e. common, rare, 
and de novo variants, both SNVs and CNVs) are likely to contribute; moreover, genetic 
















































19, 48, 49], are likely to be distributed over many hundreds of genes [50]. How these diverse and 
distributed genetic insults contribute to disease phenotypes is not well understood. 
Several studies have reduced the complexity of such analyses by considering the 
phenotypes associated with mutations in specific genes [51] or at specific loci [52, 53]. Many 
studies of monogenic (or syndromic) forms of autism (for example, due to mutations in CHD8 
[54], DYRK1A [55, 56], and MECP2 [57, 58]) have identified considerable phenotypic 
heterogeneity, even within gene-first syndromic cohorts. Similarly, diverse phenotypes are often 
associated with ASD-associated CNVs at the same locus (for example 16p11.2 [59], 7q11, and 
15q11.2-13.3 [60]). Interestingly, ASD cohorts are phenotypically diverse, even when cases are 
associated with mutations in the same gene. 
An alternate approach to studying phenotypes investigates how different types of genetic 
variation contribute to differences in phenotypes, averaged across many genes. Previous studies 
have found, for example, that LGD de novo mutations are likely to contribute to more severe 
cognitive [8] and motor skill phenotypes [24]. Other studies further suggest that the severity of 
ASD-associated behavioral phenotypes reflects contributions from both common and rare 
variants [22, 61]. These results provide important insights into the overall effects of mutation 
types. However, even for probands affected by similar types of genetic insults (for example, 
truncating de novo mutations) there remains substantial phenotypic heterogeneity [8, 16, 19, 24, 
48]. Importantly, the relationships between specific single variants and observed phenotypes in 
specific affected individuals (and why variants result in more or less severe phenotypes) are not 
well understood. 
We illustrated these open questions through a simple analysis of proband phenotypes in a 
well-studied simplex ASD cohort, the Simons Simplex Collection [62]. Specifically, we 
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compared the phenotypes between individuals who were affected by different de novo LGD 
mutations affecting the same gene. Notably, such probands harbored mutations both of the same 
type and truncating the same target gene. The differences in nonverbal IQ observed between 
such proband pairs were, at most, ~10% smaller than differences between random probands in 
the cohort (Figure 0.3). Moreover, despite the stratification in the analysis by both mutation type 
and affected gene, these differences were not statistically significant.  Our primary goal in the 
following studies was to explore the nature of and mechanisms underlying such phenotypic 
differences across individual ASD probands.  
 
Figure 0.3 Variability of phenotypes for probands with LGD mutations in the same gene. Each 
line represents the distribution of pairwise difference in nonverbal IQ (NVIQ) between probands either 
paired randomly (grey) or paired by both class of mutation and target gene (i.e. both probands had LGD 
de novo mutations affecting the same gene) (red). The x-axis represents the absolute difference in NVIQ 
between probands. The y-axis represents the probability density of the distribution. 
 
Simplex ASD as a relatively simple model of genetic disease 
In our work, we focused on the contribution of LGD de novo mutations to phenotypic 
diversity in simplex ASD. Importantly, sporadic simplex cases of ASD and, in particular, 















probands from quad families (i.e. families with unaffected siblings), are known to be strongly 
affected by de novo mutations with severe deleterious effects [8, 23, 24, 63]. Given their high 
penetrance (~20-40%) and large effect sizes, these mutations are likely to have especially 
pronounced (i.e. observable) phenotypic effects. Moreover, because such damaging mutations 
are relatively rare (~0.2 per proband), most probands (>95%) affected by an LGD mutation will 
harbor no other mutations of comparable effect size (Figure 0.4). Due to their relatively simpler 
genetic architecture, the phenotypes resulting from these cases can be attributed to single causal 
LGD mutations. Notably, simplex cohorts often display phenotypic heterogeneity comparable to 
more general ASD cohorts [8, 26, 27]. Thus, genotype-to-phenotype relationships in autism may 
be directly investigated by analyzing the properties of de novo LGD mutations and their 
associated phenotypes in affected simplex probands.  
 
Figure 0.4 Probability of observing different numbers of LGD mutations in a proband. The x-
axis represents the number of de novo LGD mutations harbored by a proband. The y-axis represents the 
probability density function, estimated as a Poisson distribution with mean parameter equal to the rate of 























2 Gene dosage changes and phenotype severity in ASD  
2.1 Introduction 
Changes in gene dosage, commonly defined as the copy number of a gene, are an 
important source of genetic variation likely to have large effects on human phenotypes. For 
example, loss of dosage, such as through copy number or truncating variation, is an important 
risk factor for many diseases. Recent large-scale genetic studies of psychiatric disorders in 
general, and of autism spectrum disorders (ASD) specifically, have demonstrated that such 
genetic insults contribute to the etiology of these diseases. However, even within simplex ASD 
cohorts, where the effects of such damaging mutations should be least affected by differences in 
genetic background, probands with truncating mutations in the same genes, i.e. with the same 
copy number of a target gene, often vary considerably in phenotype (Figure 0.3). The nature of 
these variations in phenotype is not well understood. In the presented work, we investigated how 
truncating (nonsense, splice-site, and frameshift) mutations, often called likely gene-disrupting 
(LGD) mutations, vary in their effects, both on target gene expression and on phenotypes in 
affected individuals. 
Initially we studied how LGD variants differ in their effects on gene expression. 
Importantly, the mechanisms by which LGDs change expression levels are well-understood, 
mediated by the highly evolutionarily conserved nonsense-mediated decay (NMD) pathway. 
Broadly, NMD results in the identification and degradation of mRNA transcripts containing 
premature truncating codons. However, the effects of NMD on overall expression levels are 
likely to be affected by both allele-specific expression (AE) and alternative splicing (AS). Both 
processes have been studied in humans using high-throughput approaches and are known to vary 
across genes and individuals. Thus, changes in expression due to NMD likely depend on the 
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specifics of AE and AS for the targeted gene in an affected individual. To our knowledge, no 
prior work analyzed the effects of AE and AS on NMD or modeled their combined effects to 
quantify changes in total gene expression due to specific LGD variants. In our work, we 
developed a novel approach to calculate, using RNA-seq data, the extent of NMD in the presence 
of both AE and AS. We applied our methods to characterize the varying effects of NMD 
triggered by thousands of LGD variants, in multiple human tissues, and across hundreds of 
affected individuals.  
We then investigated whether gene expression loss due to NMD was a potential 
mechanism underlying phenotypic variability in ASD. Specifically, we hypothesized that LGD 
mutations affecting the same gene would vary in their effects on target gene expression, and that 
the severity of phenotypic consequences resulting from LGDs would be correlated with the 
magnitude of the changes in expression due to NMD. To that end, we defined gene dosage not as 
the intact copy number of a gene, as it is commonly used, but as the expression level of an LGD-
affected gene relative to its wild-type expression level (i.e. the change in dosage represents the 
fraction of gene expression lost due to NMD). Using our previously developed methods to 
analyze NMD as well as genetic and phenotypic data from independent autism cohorts, we 
investigated how changes in gene dosage affect the severity of cognitive and behavioral 
phenotypes in autism. 
 Finally, we explored the quantitative relationships between changes in gene dosage 
induced by NMD and the phenotypic effects of LGD mutations. To model these relationships, 
we introduced a genetic parameter, phenotype dosage sensitivity (PDS), characterizing the 
quantitative relationship between changes in a gene’s dosage and changes in specific phenotypes. 
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Using simple parameterizations, we described how linear models of gene dosage can explain a 




Variability in NMD-induced dosage decreases for LGD mutations in different exons  
 Initially, we sought to understand how nonsense-mediated decay (NMD) due to 
truncating variants [64] affects gene dosage. To quantify changes in dosage, which we defined as 
the fraction of wild-type gene expression lost due to NMD, we developed a statistical model 
incorporating the effects of allele-specific expression (AE), alternative splicing (AS), and NMD 
of transcripts (see Methods; Figure 2.1). In our model, we assumed that heterozygous truncating 
genotypes, such as in probands with LGD mutations observed in ASD, result in transcription 
from both alleles, possibly in unequal proportions due to regulatory variation (i.e. AE). We 
further assumed that, due to splicing (AS), only a fraction of transcripts from the affected gene 
copy would include the exon harboring an LGD variant. Finally, we assumed that NMD is an 
imperfect process resulting in degradation of a fraction of transcripts susceptible due to 
incorporation of the LGD variant. In our model we parameterized each of these biological 
processes using appropriate statistical distributions and then developed an empirical Bayes 
algorithm to fit the model parameters using RNA-sequencing data (see Methods; Figure 2.2). 
 
Figure 2.1 Biological processes considered in the modeling of NMD. Each plate represents a 
gene or transcript sequence. From top to bottom, levels of the diagram represent: (1) the heterozygous 










Heterozygous LGD variant 















different isoforms, and (4) reduction in mRNA expression levels due to nonsense-mediated decay 
(NMD). Arrows between sequences represent the biological processes of allele specific expression 
(parameterized by f), alternative splicing (parameterized by the vector of isoform-specific expression 
levels, x), and NMD (parameterized by the efficiency of degradation, e). Labels next to each arrow 
represent the parameters used to model each process in the model (see Methods). 
 
Figure 2.2 Diagram illustrating data analyses used to estimate the effects of NMD. Colored 
boxes in the flow-chart represent data analyses grouped by the type of data used; counter-clockwise from 
top, blue represents analysis of sequenced exomes, grey represents the fitting of parameters to RNA-seq 
data, and beige represents the comparisons between RNA-seq data for synonymous and LGD variants. 
Inset boxes illustrate calculations used in each analysis: (a) identification of heterozygous genotypes in 
sequenced exomes, (b) mapping of RNA-seq reads to each allele, (c) quantification of isoform-specific 
expression, (d) estimation of NMD efficiency from allelic expression, and (e) estimation of NMD 
efficiency from isoform-specific expression (see Methods). 
 We applied our model to data from the ongoing Genotype and Tissue Expression (GTEx) 
Consortium project [65, 66], which collected exome sequencing and corresponding human gene 
expression data from human donors across multiple tissues. These data allowed us to investigate 
the effects of NMD on LGD variants present in human populations over thousands of genes and 
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variants in the GTEx dataset. Specifically, we analyzed allele-specific read counts [65] and 
estimated the effects of NMD by comparing read counts for truncating variants to read counts for 
synonymous variants (see Methods; Figure 2.2).  
 When we calculated the effects of NMD in GTEx, we found that truncating variants 
result on average in relatively mild effects on gene dosage (~15-30% decrease in dosage; Figure 
2.3). To quantify the dosage changes, we separately considered two limiting case assumptions. In 
our upper bound estimate, we assumed that all transcripts incorporating the LGD variant would 
result either in nonsense-mediated decay or in the translation of non-functional proteins. Under 
these assumptions, LGD variants resulted in an average dosage change of 31.0% (Figure 2.3, 
orange line). In our lower bound estimate, we assumed that all transcripts incorporating the LGD 
variant can be translated into a partial but functional protein. Under these assumptions, where the 
only loss of dosage was due to NMD, we estimated that LGD variants would cause a 16.4% 
change in dosage (Figure 2.3, purple line). In both models, we found that heterozygous 
truncating genotypes resulted in a range of possible dosage changes across approximately three 




Figure 2.3 The distribution of changes in overall gene expression dosage due to LGD variants in 
GTEx. For each LGD variant in GTEx, we calculated the relative (percent) change in total gene expression 
caused by the LGD variant in one of 10 major tissues analyzed in GTEx (see Methods); the results were 
combined across tissues. Each colored line represents the distribution of estimated dosage changes across 
all variants. The purple line represents the change in overall gene dosage due to nonsense-mediated 
decay (NMD) assuming that truncated proteins are fully functional. The distribution in orange represents 
the change in overall gene dosage assuming that all truncated proteins are nonfunctional. The vertical 
dashed lines represent the average of each distribution. 
We then investigated differences in NMD across tissues. We found that across hundreds 
of genes, the average NMD efficiency across tissues was similar, with inter-tissue efficiencies of 
0.55-0.82 (mean = 0.68; SD = 0.07; CV = SD/mean = 0.097). We also found that the standard 
deviation of efficiency across variants in a given tissue was inversely correlated with the average 
efficiency observed in the tissue (Pearson’s R = -0.74, p = 6´10-5; Spearman’s ρ = -0.73, p = 
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Figure 2.4 Relationship between averages and standard deviations of NMD efficiency in tissues. 
Each point represents one of ten tissues from GTEx used to estimate the efficiency of NMD. The x-axis 
represents the average efficiency of NMD observed in the tissue. The y-axis represents the standard 
deviation of NMD efficiency in the tissue. Statistics for efficiency were calculated across all rare 
heterozygous LGD variants. 
Truncating variants in highly expressed exons should lead, on average, to relatively larger 
NMD-induced decreases in overall gene dosage. To confirm this hypothesis, we calculated, for 
each exon harboring a truncating variant, its expression level relative to the expression level of 
the corresponding gene. We then explored the relationship between the relative expression of 
exons and the observed NMD-induced decreases in gene expression. The analysis indeed 
revealed a strong correlation between the relative expression levels of exons harboring LGD 
variants and the corresponding changes in overall gene dosage (Figure 2.5; Pearson’s R = 0.69, p 

















































Figure 2.5 Relationship between the relative expression of exons containing LGD variants and 
the corresponding NMD-induced decreases in overall gene expression. Each point corresponds to the 
quantification of NMD, in one of ten human tissues, for an LGD variant. The x-axis represents the relative 
expression of the exon harboring an LGD variant in a tissue; the relative expression of an exon was 
calculated as the ratio between the exon expression and total expression of the corresponding gene (see 
Methods). The y-axis represents the NMD-induced decrease in overall gene expression (see Methods). 
Red line represents a moving average of the data, calculated on an interval of width 0.1 (log-scaled). 
 To validate our findings, we analyzed data from a CRISPR/Cas9 genetic editing 
experiment in HAP1 cell lines [67, 68], in which nearly all possible single nucleotide variants 
(~3,900 SNVs, including 130 LGDs) were introduced into target exons in the BRCA1 gene. 
Changes in dosage were quantified by calculating the mRNA expression level for cells affected 
by an LGD mutation relative to the expression levels measured in cells with synonymous 
mutations. Reassuringly, the observed NMD efficiency in these experiments was similar to the 
estimates we made using GTEx data (mean = 0.59, SD = 0.24). In addition, we indeed found that 
the relative expression of target exons (i.e. expression level of the exon divided by expression 
level of the gene) correlated with changes in dosage due to NMD triggered by LGD mutations in 
the exon (Pearson’s R = 0.65, p = 0.02; Spearman’s r = 0.61, p = 0.03; Figure 2.6). 
ρSpearman = 0.81 (P < 2×10-16)
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Figure 2.6 Relationship between relative exon expression and change in dosage due to NMD in 
BRCA1 experiments. Each point represents an exon in BRCA1 targeted for mutagenesis in saturation 
genetic editing experiments. The x-axis represents the relative expression of the exon, defined as the 
average expression level of the exon divided by the average expression level of the gene. The y-axis 
represents the observed change in BRCA1 gene dosage due to LGD mutations in the exon. Error bars 
represents the SEM. 
 We then asked whether the de novo LGD mutations contributing to ASD would also 
similarly vary in their effects on target gene expression. To that end, we analyzed de novo LGD 
mutations identified in ~2500 sequenced probands in the Simons Simplex Collection (SSC) [62] 
When we applied our model of NMD to estimate the dosage changes (i.e. fraction of wild-type 
expression lost) due to LGD mutations in these datasets, we indeed found that changes in dosage 
varied substantially across mutations (mean = 0.28; SD = 0.18; CV = SD/mean = 0.65; Figure 
2.7). In these calculations, we used the underlying distribution parameters fitted to data from all 
brain samples in GTEx.  
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Figure 2.7 Distribution of estimated dosage changes for LGD mutations in SSC. The histogram 
represents the distribution of the predicted dosage changes resulting from NMD of LGD mutations in 
SSC. The x-axis (log-scaled), represents the estimated change in dosage. The y-axis represents the number 
of LGD mutations in SSC. Dosage changes were estimated based on a moving average of dosage changes 
observed in brain tissues in GTEx (see Methods). 
  Based on these results, we hypothesized that differences in dosage lost due to NMD of 
LGD mutations could contribute in part to the phenotypic variability between ASD probands. To 
investigate, we asked whether larger changes in gene dosage from LGD mutations would lead to 
more severe disease phenotypes in autism. In the initial analysis, we considered several cognitive 
phenotypes, full-scale (FSIQ), nonverbal (NVIQ), and verbal (VIQ) intelligence quotients (IQ) 
[5, 8, 10], available in SSC. These scores are normalized by age and standardized across a broad 
range of phenotypes [28]. To account for differences in function across genes, we compared only 
probands with LGD mutations in the same gene. Specifically, for each gene with multiple LGD 
mutation in SSC, we stratified probands based on whether the LGD mutations affecting them 
induced higher or lower than average dosage changes, compared to the average for the gene. 
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affected by smaller dosage change, differing, on average, by 11.6 full-scale, 13.5 nonverbal, and 
9.5 verbal IQ points (Figure 2.8; FSIQ, NVIQ, VIQ Wilcoxon signed-rank one-tail p = 0.04, 
0.01, 0.1). Moreover, across all probands with mutations in these genes, larger dosage changes 
were correlated with the lower absolute IQ phenotype scores (FSIQ, NVIQ, VIQ Pearson’s R = -
0.27, -0.31, -0.17; one-tail p = 0.03, 0.01, 0.19; Spearman’s r = -0.19, -0.28, -0.11; one-tail p = 
0.12, 0.023, 0.4). 
.  
Figure 2.8 IQ phenotypes in probands with LGDs in exons with lower- and higher-than-average 
expression. Along the x-axis, from left to right, pairs of boxplots are plotted for full-scale (FSIQ), 
nonverbal (NVIQ), and verbal (VIQ) IQ scores. The y-axis represents the relative IQ score of a proband, 
defined as the relative deviation of each IQ from the average (i.e. (𝒙 − 𝝁𝑿)/𝝁𝑿). Boxplots show the 
distribution of relative IQs for probands with LGD mutations in exons with lower-than-average (blue) 
and higher-than-average (red) expression. The bar in the middle of each box represents the median; the 
top and bottom of the boxes represent, respectively, the 75th and 25th percentiles. The whiskers represent 
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Variability in the sensitivity of phenotypes to changes in the dosage of different genes 
 We sought to further investigate the relationship between changes in gene dosage and 
changes in autism phenotypes. It is likely that there is substantial variability across human genes 
in terms of the sensitivity of intellectual and other ASD phenotypes to gene dosage. Therefore, to 
quantify the sensitivity of a phenotype, for example IQ, to changes in the expression of specific 
genes, we considered a simple linear dosage model (see Methods). In the model, we assumed for 
genes with recurrent truncating mutations in SSC that changes (decreases) in probands’ IQs are 
linearly proportional to the predicted decrease in overall gene dosage due to NMD. We further 
assumed that each human gene can be characterized by a parameter, which we call its phenotype 
dosage sensitivity (PDS), characterizing the linear relationship between changes in gene dosage 
compared to wild type and the corresponding changes in a given human phenotype. Numerically, 
we defined IQ-associated PDS to be equal to the average change in IQ resulting from a 10% 
change in gene dosage. 
To calculate the sensitivity of IQ phenotypes in autism to changes in dosage, we used the 
BrainSpan dataset [69], which contains exon-specific expression from human brain tissues. The 
BrainSpan data allowed us to estimate expression dosage changes resulting from LGD mutations 
in different exons (see Methods). Using the linear model, for each gene with recurrent truncating 
ASD mutations, we used predicted changes in gene dosage to estimate gene-specific PDS 
parameters for intellectual phenotypes (see Methods). Notably, as we expected, PDS values 
varied substantially across 24 considered human genes (CV = SD/Mean = 0.59, 0.57, 0.72 for 
FSIQ, NVIQ, VIQ). We restricted this analysis to LGD mutations predicted to cause NMD-
induced expression changes, i.e. we excluded mutations within 50 bp of the last exon junction 
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complex [70], and also assumed the average neurotypical IQ (100) for wild type (intact) gene 
dosage.  
 
Figure 2.9 Distribution of the sensitivity of IQ phenotypes to changes in gene dosage, i.e. the 
Phenotype Dosage Sensitivity (PDS), across different ASD genes with recurrent truncating mutations in 
SSC. From left to right, the histograms show the distribution of PDS sensitivity parameters across genes 
for (a) full-scale IQ (FSIQ), (b) nonverbal IQ (NVIQ), and (c) verbal IQ (VIQ). To calculate PDS 
parameters, we used linear regression, separately for each gene, to fit the relationship between the 
observed IQ decrease compared to the neurotypical average value (100) and the estimated change in gene 
dosage due to LGD mutations (see Methods). We then calculated PDS as the predicted decrease in IQ due 
to 10% decreases in gene dosage. 
 
Relationships between gene dosage changes and the severity of ASD phenotypes 
We used the aforementioned linear model to explore the relationship between the relative 
expression values of exons (i.e. the ratio of exon expression to gene expression) harboring LGD 
mutations and the corresponding decreases in probands’ intellectual phenotypes. To account for 
differences in phenotypic sensitivity to dosage changes across genes, we normalized the 
observed changes in IQ by the estimated PDS values of affected genes. Normalized in this way, 
phenotypic effects represent changes in phenotype relative to the predicted effects for 10% 
decreases in dosage of affected genes. This analysis revealed that mutation-induced gene dosage 
changes are indeed strongly correlated with the normalized phenotypic effects (FSIQ/NVIQ/VIQ 
Pearson’s R = 0.56, 0.63, 0.51; permutation test p = 0.03, 0.02, 0.02; Figure 2.10). Very weak 
(a) (b) (c)
average: 12.0 average: 11.4 average: 11.4
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correlations were obtained for randomly permuted data, i.e. when truncating mutations were 
randomly re-assigned to different exons in the same gene (average FSIQ/NVIQ/VIQ Pearson’s R 
= 0.11, 0.18, 0.01; SD = 0.23, 0.20, 0.21; see Methods). Since the heritability of intelligence is 
known to substantially increase with age [71], we also investigated how the results depend on the 
age of probands. When we restricted our analysis to the older half of probands in SSC (i.e. older 
than the median age of 8 years), the strength of the correlations between the predicted dosage 
changes and normalized phenotypic effects increased further (FSIQ/NVIQ/VIQ Pearson’s R = 
0.68, 0.75, 0.60; permutation test p = 0.03, 0.019, 0.05; Figure 2.11). The strong correlations 
between target exon expression and intellectual ASD phenotypes suggest that, when gene-
specific PDS values are taken into account, a significant fraction (30%-45%) of the relative 
phenotypic effects of de novo LGD mutations across genes can be explained by the resulting 
dosage changes of target genes. 
 
Figure 2.10 Relationship between the relative expression of exons harboring LGD mutations and 
the corresponding decreases in probands’ IQs. From left to right, the scatterplots show (a) full-scale IQ 
(FSIQ), (b) nonverbal IQ (NVIQ), and (c) verbal IQ (VIQ) scores. Each point in the scatterplots 
corresponds to a proband in SSC affected by an LGD mutation; only genes with recurrent LGD mutations 
in SSC were considered. The x-axis represents the relative expression, i.e. the ratio of exon expression to 
total gene expression, of the exon harboring the LGD mutation. The y-axis represents the proband’s 
observed decrease in IQ (relative to wild-type score of 100) normalized by the Phenotype Dosage 
Sensitivity (PDS) parameter of each gene (see Methods). Red dashed lines represent the linear regression 




Figure 2.11 Relationship between the relative expression of exons harboring LGD mutations and 
the corresponding decrease in probands’ intellectual phenotypes for the older half of probands in SSC 
(i.e. older than the median age 8.35 years). From left to right, the scatterplots show (a) full-scale IQ (FSIQ), 
(b) nonverbal IQ (NVIQ), and (c) verbal IQ (VIQ) scores. Each point in the scatterplots corresponds to a 
proband in SSC affected by an LGD mutation; only genes with recurrent LGD mutations in SSC were 
considered. The x-axis represents the relative expression, i.e. the ratio of exon expression to total gene 
expression, of the exon harboring the LGD mutation. The y-axis represents the proband’s observed 
decrease in IQ (relative to wild-type score of 100) normalized by the Phenotype Dosage Sensitivity (PDS) 
parameter of each gene (see Methods). Red dashed lines represent the linear regression fits across all 
points. 
We then applied our linear model to study the effects of dosage changes on another 
quantitative phenotype, adaptive behavior. In SSC and the independent Simons Variation in 
Individuals project (VIP) [29], behavioral adaptability was scored using the Vineland Adaptive 
Behavior Scales (VABS) [72], which contained overall composite scores as well as subscores for 
communication, daily living skills (DLS), and socialization. When we applied the linear dosage 
model while accounting for the sensitivity of VABS phenotypes to changes in the dosage of 
different genes (i.e. gene-specific PDS values), we found that normalized VABS phenotypes also 
correlated with the relative expression of exons harboring LGD mutations. (Pearson’s R = 0.75, 
permutation test p = 0.003; Figure 2.12). Results were consistent in the independent  SSC and 
VIP datasets (in SSC, for example, Pearson’s R = 0.73, permutation test p = 0.013). Notably, IQ 
RPearson = 0.68 RPearson = 0.75 RPearson = 0.60
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and VABS scores were only weakly correlated (for NVIQ and VABS composite scores, 
Pearson’s R = 0.46, p = 1.50´10-4).  
 
Figure 2.12 Relationship between the relative expression of exons harboring LGD mutations and 
the corresponding decrease in probands’ adaptive behavior phenotypes, i.e. Vineland Adaptive Behavior 
Scales (VABS) in SSC and VIP probands. From top left, the scatterplots show standardized VABS (a) 
composite, (b) communication, (c) daily living skills, and (d) socialization scores. Each point in the 
scatterplots corresponds to a proband in SSC or VIP affected by an LGD mutation; only genes with 
recurrent LGD mutations across both datasets were considered. The x-axis represents the relative 
expression, i.e. the ratio of exon expression to total gene expression, of the exon harboring the LGD 
mutation. The y-axis represents the proband’s observed decrease in VABS score (relative to wild-type 
score of 100) normalized by the Phenotype Dosage Sensitivity (PDS) parameter of each gene (see 
Methods). Red dashed lines represent the linear regression lines across all points. 
 Using the developmental expression data available in BrainSpan, we then asked whether 
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resulting proband phenotypes. To that end, we performed the linear model analysis, i.e. 
normalizing for the sensitivity of phenotypes to each gene, using relative exon expression data 
from each of six developmental periods: early, mid, and late prenatal stages, infancy/childhood, 
adolescence, and adulthood. In our analysis, we did not find significant differences between 
relative expression levels at different developmental periods (Figure 2.13). 
 
Figure 2.13 Correlation between relative exon expression and normalized phenotypic effects 
across development. From left to right, the x-axis represents different developmental periods arranged in 
temporal order. The y-axis represents the correlation between relative expression and normalized 
phenotypic effects on nonverbal IQ. Relative expression was calculated as mean exon expression level 
divided by the mean gene expression level in each developmental period. Correlations were calculated 
using the linear dosage/PDS model (see Methods). Error bars represent standard deviations estimated by 
statistical bootstrapping. 
 
Inference of quantitative phenotypes based on changes in gene dosage 
We then evaluated the ability of our linear dosage model, based on calculated PDS 































































































for each gene with multiple truncating mutations in different probands, we used our linear 
regression model to perform leave-one-out predictions for IQ scores, i.e. we used PDS values 
calculated based on all but one probands with mutations in the gene to estimate IQ values for the 
left out proband (Figure 2.14, inset; see Methods). Despite the simplicity of our model, for LGD 
mutations that trigger NMD, the model predictions (Figure 2.14, Figure 2.15) were significantly 
smaller than the median differences between probands with LGD mutations in the same gene 
(median prediction errors for FSIQ/NVIQ/VIQ were 12.2, 11.0, 20.6 points; same gene median 
IQ difference 24.0, 22.0, 30.5 points; MWU one-tail test p = 0.019, 0.014, 0.017). The inferences 
based on probands of the same gender (Figure 2.14, Figure 2.15) had significantly smaller errors 
compared to inferences based on probands of the opposite gender (same gender 
FSIQ/NVIQ/VIQ median error 11.1, 9.1, 15.9 points; different gender median error 19.0, 19.9, 
33.0 points; MWU one-tail test p = 0.03, 0.018, 0.02). Moreover, as expected based on our 
previous analyses, prediction errors decreased for older probands; for example, for probands 
older than 12 years, median FSIQ/NVIQ/VIQ error 7.0, 7.6, 10.0 points (Figure 2.14, Figure 




Figure 2.14 Boxplots represent the distribution of errors in predicting the effects of LGD 
mutations on NVIQ (see Methods); NVIQ prediction errors are shown for all probands (green), and for 
probands older than 12 years (purple). For comparison, the average differences in NVIQ scores between 
probands with LGD mutations in the same gene are also shown (blue). Only genes with multiple LGD 
mutations in SSC were considered. The ends of each solid box represent the upper and lower quartiles; 
the horizontal lines inside each box represent the medians; and the whiskers represent the 5th and 95th 
percentiles. The inset panel illustrates the linear regression model used to perform leave-one-out 
predictions of probands’ NVIQs. Round open points represent observed phenotypic scores for probands 
with LGD mutations in the same gene, the grey square point represents the predicted phenotypic score, 
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Figure 2.15 Distribution of the errors in predicting the effect of LGD mutations on IQ scores 
based on the linear dosage model. The errors are shown for all probands (green), and for probands older 
than 12 years (purple); for comparison, the distribution of IQ differences between all probands with LGD 
mutations in the same genes are also shown (blue). From left to right, plots represent the distribution of 
score differences for (a) full-scale IQ (FSIQ), (b) nonverbal IQ (NVIQ), and (c) verbal IQ (VIQ). The ends 
of each solid box represent the upper and lower quartiles, the horizontal lines within each box represent 





Figure 2.16 Median error in predicting the effects of LGD mutations on IQs for older probands 
in SSC. From left to right, plots represent the median prediction errors for (a) full-scale IQ (FSIQ), (b) 
nonverbal IQ (NVIQ), and (c) verbal IQ (VIQ). The x-axis represents the minimum age of probands used 
for leave-one-out predictions. The y-axis represents the median prediction error based on the linear 
dosage model. Error bars were estimated using bootstrapping. 
 Interestingly, we observed in these analyses that the inference errors differed across 
probands with relatively lower and higher IQ scores. For example, we observed smaller 
inference errors for probands with IQ >70 compared to ASD probands with IQ ≤70 (for IQ >70 
median NVIQ error = 11.0, for IQ ≤70 median error = 16.4; Mann-Whitney U one-tail test p = 
0.08). To further explore these differences between the lower and higher IQ probands, we 
investigated whether using the relative expression of exons during different developmental 
periods would result in more accurate phenotypic predictions in each cohort. Given the 
substantial differences in predictions error, we separately investigated phenotypic predictions for 
the lower IQ (≤70) and higher IQ (>70) probands. Interestingly, we found (Figure 2.17a) that 
using relative exon expression in early- and mid-prenatal developmental periods resulted in 
significantly more accurate (by ~35%) phenotypic predictions specifically for lower IQ 
probands. In contrast, for higher IQ probands we observed (Figure 2.17b) similar accuracy of 
phenotypic predictions based on exon expression data from different developmental periods. 
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This result suggests that expression of prenatally biased exons is significantly more informative 
for phenotypes of the lower IQ cohort. 
 
Figure 2.17 Prediction errors using relative expression measured during different 
developmental periods. For each of six broad developmental periods, we calculated the relative 
expression of exons targeted by LGD mutations in SSC. We used development-specific relative 
expression to make leave-one-out predictions of IQ for probands affected by each mutation (see 
Methods). Boxplots represent the prediction errors for (a) lower IQ probands (nonverbal IQ ≤ 70) and (b) 
higher IQ probands (nonverbal IQ > 70). The x-axis represents the six developmental periods for which 
predictions were made. The y-axis represents the relative error of predictions, normalized to the average 
error across all periods. Horizontal dotted lines indicate the expected median error for predictions based 































































SSC sequencing and phenotype data 
We used exome sequencing and ASD probands’ phenotypic data available in the Simons 
Simplex Collection (SSC) [28]. De novo LGD mutations were obtained from Iossifov et al. [8]. 
As a source of phenotypic data, we used the Prepared Phenotype Dataset (v15) from the SFARI 
Base online data portal (sfari.org/resources/sfari-base). The SSC inclusion/exclusion criteria, 
phenotype profiling instruments, and sequencing protocols have been described in previous 
publications [20, 28, 36, 73, 74]. 
To identify the effects of mutations on gene transcripts, we analyzed variants in SSC 
using Ensembl’s Variant Effect Predictor (VEP) tool, which provides multiple annotations for 
each mutation based on its predicted effects on different  transcriptional isoforms of a gene 
(grch37.ensembl.org/info/docs/tools/vep) [75]. For each mutation in SSC, we used VEP to 
identify likely gene-disrupting (LGD) mutations by searching for the following predicted 
consequences: nonsense (translational stop gained) variants, frameshift indels, splice acceptor 
variants, and splice donor variants. 
 
VIP sequencing and phenotype data 
We used sequencing and phenotypic data available in the Simons Variation in Individuals 
Project (VIP) [29]. De novo LGD mutations and the corresponding phenotype scores for affected 
probands were obtained from the Simons VIP Phase 2 Single Gene Dataset v4.0, available from 




Phenotype scores analyzed in SSC and VIP 
Both SSC and VIP include ASD probands of both genders spanning a broad range of 
ages and phenotypic abilities. In our analyses, we considered IQ scores (available for SSC only) 
and Vineland Adaptive Behavior Scales scores (available for both SSC and VIP). Both are 
normalized to account for developmental differences and hence were suitable for direct 
comparison between probands. 
 
GTEx genotype and expression data 
To investigate the dosage effects across human tissues resulting from protein-truncating 
variants, we used data from the Genotype-Tissue Expression (GTEx) project [76]. Processed 
RNA-seq data, including expression data summarized to genes, isoforms, and exons, were 
obtained through the consortium’s online data portal (https://www.gtexportal.org/). Raw 
sequencing and genotype data were obtained via NCBI’s Database of Genotypes and Phenotypes 
(dbGaP) (Study Accession: phs000424.v6.p1), available online (ncbi.nlm.nih.gov/gap). For 
RNA-seq data, we obtained SRA submitted files; these files contained the binary alignment map 
(BAM) for each RNA-seq experiment. In the analysis, we considered samples from ten major 
human tissues: adipose (subcutaneous), tibial artery, brain, heart (left ventricle), lung, skeletal 
muscle, tibial nerve, skin (not sun-exposed), thyroid, and whole blood.  
In the downloaded genotype data, we identified small indels (£ 6 bp) and single-
nucleotide variants that were called using exome sequencing of 180 individuals (v6 from June 
2014). Sequencing and variant calling protocols were previously described in Melé et al. [77]. 
To explore the dosage effects resulting from heterozygous variants, we included only 
heterozygous genotypes in our analysis. To limit the number of false positive genotypes, we only 
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used calls with quality ≥ 20 (Phred-scale) for SNVs, and ≥ 30 for indels. In addition, to minimize 
the potential for downstream mapping and short read alignment biases, we excluded SNVs with 
non-unique flanking regions, based on UCSC mappability tracks. For SNVs, we excluded 
variants with 50 bp mappability less than one. For indels, we excluded variants with 36 bp 
mappability less than one. We limited our study to autosomal and rare variants (defined as allele 
frequency ≤ 0.05). 
 
Quantification of allele-specific expression (AE) 
AE for GTEx variants was quantified using RNA-seq data. In general, we followed 
previously developed protocols based on re-alignment of reads to local sequences containing 
either wild-type (WT) or variant alleles (tllab.org/data-software) [65]. For each individual, we 
first identified heterozygous genotypes and then extracted the flanking (±100 bp) reference 
genome sequences around each variant to produce a set of local sequences containing WT 
alleles. Next, we substituted the variant allele into each sequence to reflect the genotyped 
truncating variant, producing a matching set of local sequences with variant alleles. Short reads 
from RNA-seq experiments from an individual were then realigned separately against the 
reference and alternate sequences. To quantify the expression of each allele, we counted the 
number of reads aligning uniquely and without error to the WT and variant sequences, 
respectively. These numbers were then used as allele counts reflecting AE. 
To extract flanking reference sequences, we used the fastaFromBed tool from the 
bedtools software suite (v.2.23.0) [78]. All reference sequences were taken from the human 
reference genome (hg19) provided by GTEx (gtexportal.org). For aligning short reads, we used 
BWA (v.0.7.3) [79], and kept only alignment calls with base quality ≥ 10 and mapping quality ≥ 
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35. Following the methods in Rivas et al. [65], we restricted our analysis to samples with at least 
8 mapped reads, and to variants with median allele frequency, across all tissues, ≤ 0.95 and ≥ 
0.05. 
 
Gene expression changes due to LGD variants in GTEx 
To quantify altered gene expression due to an LGD variant, we considered the changes in 
expression (𝛥𝑥) compared to wild type as a combined effect of allele-specific expression (AE), 
alternative splicing (AS), and nonsense-mediated decay (NMD). To account for AE, we reasoned 
that only a fraction of total mRNA would be transcribed from each allele. To account for 
alternative splicing, we reasoned that transcripts would be spliced into multiple transcript 
isoforms, only some of which would retain the exon with the truncating mutation. Finally, we 
assumed that nonsense-mediated decay is an imperfect degradation process, in which some 
fraction of LGD-containing mRNA escapes NMD. Formally, we represented a change in 
expression as: 
𝛥𝑥 = 𝑓 ⋅ 𝜖 ⋅ 𝑥!"#$							(1) 
where the parameter 𝑓 (ranging from 0 to 1) quantifies the fraction of total transcription from the 
allele harboring the LGD variant, the parameter 𝜖 (ranging from 0 to 1) quantifies NMD 
efficiency, and 𝑥!"#$ represents the wild-type expression level of transcripts with the LGD-
containing exon, i.e. transcripts susceptible to NMD. 
Because post-NMD expression levels are experimentally observed, the relationship 
between measured and wild-type expression levels can be expressed as: 
𝑥!"#$% = 𝑥!"#$ − 𝛥𝑥							(2) 
45 
 
where 𝑥!"#$% represents the experimentally observed expression. Combining equations (1) and (2), 
we can express the effects of NMD in terms of 𝑥!"#$% : 
𝛥𝑥 =
𝑓 ⋅ 𝜖
1 − 𝑓 ⋅ 𝜖 ⋅ 𝑥!"#$
% 							(3) 
In order to estimate 𝛥𝑥 for each gene, we needed to infer the parameters 𝑓 and 𝜖, which quantify 
AE and NMD efficiency respectively. As we describe in the following sections, we inferred 
these parameters probabilistically by fitting appropriate distributions. Notably, because we were 
interested in comparing the effects of NMD across different tissues, and since the efficiency of 
NMD may vary across tissues, we performed separate analyses for each tissue. 
 
Parametric inference of AE  
To model the expected distribution of 𝑓 for each gene, we considered the AE observed 
for rare synonymous variants in the gene because such variants are unaffected by NMD. We 
considered a hierarchical model in which the distribution of 𝑓 can be modeled as a beta 
distribution (𝑓 ∼ 	Beta3𝛼& , 𝛽&7), with hyperparameters 𝛼& and 𝛽&. In the model, each specific 
measurement of a synonymous variant’s AE represents a binomial sample with parameter 𝑓 
drawn from the beta distribution: 𝑘 ∼ Binomial(𝑛, 𝑓), where 𝑛 is the total number of reads from 
both copies of the gene, and 𝑘 is the total number of reads from the synonymous variant allele. In 
this formulation, the inference of the underlying parameters can be performed by fitting a 
standard hierarchical beta-binomial model [80, 81]. To model the distribution of 𝑓 in a given 
gene, we used the maximum a posteriori estimators for the beta distribution: 
𝛼?& , 𝛽@& = argmax
'",)"





⋅ 𝑃3𝛼& , 𝛽&7							(4) 
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Here, 𝑣 indexes a specific synonymous variant from the set of all such variants 𝑉12$., and 𝑖 
indexes a specific individual carrying the variant allele, where 𝐶* is the set of all carriers. 𝑘*,+ 
and 𝑛*,+ are, respectively, the number of reads mapped to the synonymous allele 𝑣 and the total 
number of reads mapped in an AE experiment. 
To perform the maximization in equation (4), we used a standard re-parameterization of 
3𝛼& , 𝛽&	7 into 𝑢 =
'"
'"4)"
 and 𝑣 = ,
5'"4)"
 [82]. The parameters (𝑢, 𝑣) represent the mean and 
approximate standard deviation of the Beta distribution. To find values that maximize the 
posterior probability, we divided the parameter space into a discrete grid and used a grid search 
algorithm. For the hyperprior distributions, we chose a uniform distribution for the mean and a 
commonly used half-Cauchy distribution for the variance [83]. 
Note that the resulting estimators are based on multiple synonymous variants, each of 
which can have multiple individual carriers in the study population. Importantly, we only 
considered individuals with matched common synonymous variant alleles in the gene. As a 
result, the variance of the fitted distributions accounts for differences across both haplotypes and 
individuals. To minimize undersampling effects, we limited our analysis to genes with at least 
four different synonymous mutations and at least ten individual carriers. 
 
Parametric inference of NMD efficiency 
To infer NMD efficiency (𝜖), we compared the observed AE for LGD variants in GTEx 
to the expected AE estimated based on synonymous variants in the affected genes. The relative 
difference between the observed and expected values was then used to quantify the efficiency of 
NMD. Since experimental measurements for LGD variants are relatively sparse (on average, one 
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experiment per carrier of each LGD variant), we used an empirical Bayes approach to fit a 
hierarchical model. Specifically, we first used the observed AE for all LGD variants to infer the 
distribution of NMD efficiency across variants, and then we estimated the likely efficiency of 
NMD for specific variants. 
We assumed that NMD would function with some efficiency 𝜖 ∈ 	 [0,1], and modeled the 
distribution of 𝜖 using a Beta distribution (𝜖 ∼ Beta(𝛼6 , 𝛽6)). In this model, each AE 
measurement for an LGD variant 𝑣 corresponds to a binomial sample (𝑘 ∼ Binomial(𝑛, 𝑝)), 
where 𝑘 is the number of reads with the LGD variant, 𝑛 is the total number of reads, and 𝑝(𝑓, 𝜖) 
is the underlying sampling parameter which depends on the AE parameter 𝑓 of the LGD allele 
and the NMD efficiency 𝜖. 𝑝(𝑓, 𝜖) can be expressed as: 
𝑝(𝑓, 𝜖) =
𝑓 ⋅ (1 − 𝜖)
(1 − 𝑓) + 𝑓 ⋅ (1 − 𝜖) =
𝑓 ⋅ (1 − 𝜖)
1 − 𝑓 ⋅ 𝜖 							
(5) 
Where the numerator expresses the amount of post-NMD mRNA containing the LGD allele, and 
the denominator expresses the total amount of post-NMD mRNA from both alleles. 
To learn the distribution of 𝜖 across variants, we searched for parameter values that would 
maximize the posterior probability given all experimental observations. Formally, the 
maximization can be written: 
𝛼?6 , 𝛽@6 = argmax
'(,)(






⋅ 𝑃(𝛼6 , 𝛽6)	
(6) 
Here, 𝑣 indexes a specific LGD variant drawn from the set of all analyzed LGD variants (𝑉789). 
The term 𝑃*3 𝑘 ∣∣ 𝑛, 𝑝(𝑓, 𝜖) 7 represents the likelihood to observe AE for an LGD variant 𝑣. 
However, since 𝑝(𝑓, 𝜖), the binomial rate parameter, depends on 𝜖 and 𝑓 (see Eqn. 5), the 
calculation of each likelihood requires integration across both parameters. Overall, the procedure 
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searches for a distribution for 𝜖 that best explains deviations of AE for LGD variants from the 
expected AE distribution for each affected gene. The distribution of 𝜖 gives the likely percent 
decrease in expression due to NMD. 
To perform the optimization, we re-parameterized the beta distribution using mean and 
variance parameters 𝑢 = '(
'(4)(
 and 𝑣 = ,
:'(4)(
. Then we divided the parameter space into a 
discrete grid and calculated the posterior probability at each value of (𝑢, 𝑣). For the hyperprior 
distributions, we chose a uniform distribution for the mean and a half-Cauchy distribution for the 
variance parameter. We calculated the double integrals in Equation (6) numerically using 
Newton-Cotes cubature. 
Using the maximum a posteriori values for parameters (𝛼6 , 𝛽6), we then inferred 
estimates of NMD efficiency for individual LGD variants. For each variant, we searched for 
maximum a posteriori estimates of specific values of 𝜖: 
𝜖̂ = argmax
;
𝑃3 𝑘 ∣∣ 𝑛, 𝑝(𝜖) 7 ⋅ 𝑃3 𝜖 ∣∣ 𝛼?6 , 𝛽@6 7 							(7)
	 = argmax
;
EF 𝑃3 𝑘 ∣∣ 𝑛, 𝑝(𝑓, 𝜖) 7 ⋅ 𝑃3 𝑓 ∣∣ 𝛼?& , 𝛽@& 7 ⋅ 𝑑𝑓
,	
-
J ⋅ 𝑃3 𝜖 ∣∣ 𝛼?6 , 𝛽@6 7 							(8)
 
The prior term was calculated directly from the parameters 𝛼?6 and 𝛽@6. To calculate the total 
likelihood of (𝑘, 𝑛), which depends on rate parameter 𝑝, we integrated over possible values of 𝑓. 
The maximization in Equation (8), performed for each LGD variant separately, estimates the 
efficiency of NMD for a specific observed variant. 
In our implementation, we estimated values of 𝜖̂ using a one-dimensional parameter-
scanning algorithm. For each value of 𝜖, we evaluated the integral over 𝑓 numerically, using 




Changes in total gene expression due to LGD variants 
Statistical inference of the parameters 𝑓 and 𝜖, described in the previous sections, 
allowed us to compute the changes in expression due to each LGD variant (see Eqn. 1). To 
account for differences in absolute expression level across genes, we normalized the effects of 








Where 𝑥?!$! is the total amount of mRNA expressed and 𝑥?!$!%  is the experimentally measured 
mRNA expression. In this way, 𝛥𝑥=!> expresses the normalized (fraction) change in target gene 
expression due to NMD. In our analyses, we compared 𝛥𝑥=!> to the relative expression of exons, 
defined as the expression level of the target exon divided by the total expression level of the 
gene. 
 
Estimation errors for AE and NMD efficiency 
 To evaluate our model, we generated synthetic read counts by simulating the RNA 
sequencing of variants in genes. We used simulated synonymous variants (i.e. AE datasets) to 
evaluate our statistical model’s ability to recover parameters 𝛼& and 𝛽& for allele-specific 
expression. We then used simulated LGD variants (i.e. NMD datasets), including the loss of 
alternative-allele reads due to NMD, to evaluate our model’s ability to fit parameter 𝜖 for 
specific variants.  
For each synthetic AE dataset, we simulated the allele-specific expression of the gene by 
randomizing parameters for 𝛼& and 𝛽& to generate an underlying distribution for the parameter 𝑓. 
We sampled from the distribution to generate specific values of 𝑓 in an individual. Then, for 
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each individual, we performed a random binomial sample to generate a specific observation of 
reads. The number of reads in each binomial sample was randomly chosen from a Poisson 
distribution to match the minimum number of reads in each observation in our experimental 
dataset (𝜆 = 8). 
 
Figure 2.18 Estimation errors for the distribution of allele-specific expression for different 
dataset sizes. In each plot, the x-axes represent the number of observations in each synthetic dataset. The 
y-axes represent the (log10-scaled) estimation errors for the scale (left) and center (right) parameters of the 
AE distribution. Each boxplot represents a distribution of errors observed across 1000 synthetic datasets. 
The bars inside of each box represent the median; the top and bottom of each box represent the 25th and 
75th percentiles; the whiskers represent the upper and lower bounds of the 95% confidence interval; 
points represent outliers. 
 We then applied our model of AE (see Eqn. 4) to calculate the underlying distribution of 
𝑓 for each gene in our synthetic dataset. To evaluate the accuracy of the inference, we calculated 
the percent error in the resulting (fitted) estimates relative to the initially generated values. 














































































number of sequenced reads. Across a randomly generated pool of 10,000 simulated genes, we 
observed ~3%	error in the estimation of the mean, and ~10% error in the estimation of the scale 
parameter (Figure 2.18). As expected, these errors were inversely proportional to the number of 
observations. 
 
Figure 2.19 Estimation error of NMD efficiency. Each boxplot represents a distribution of 
average estimation errors in synthetic datasets. The x-axis represents the number of observations in each 
dataset. The y-axis represents the average estimation error across observations in each dataset. Bars in 
each box represents the median; top and bottom of each box represent the 25th and 75th percentiles; 
whiskers represent the 95% confidence interval, and points represent outliers. Each boxplot represents a 
distribution of average errors across 1000 synthetic datasets. 
 To generate NMD datasets, for each dataset, we generated randomized parameters 𝛼6 and 
𝛽6, characterizing the distribution of efficiencies for NMD. As we did previously, we generated 
individual distributions of AE for genes and sampled values of 𝑓 from the distribution. We then 
randomly selected a value 𝜖 from the underlying distribution of NMD efficiency. We simulated 
the number of reads from each allele by drawing from a binomial distribution with the 




























Number of observations in synthetic data
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variation of efficiency across genes, variants, and individuals, as well as statistical noise from the 
small number of reads observed. 
 We evaluated our model’s ability to infer NMD efficiency by calculating, for each 
variant, the estimation error, defined as the absolute difference in efficiency between the 
estimated (𝜖̂) and actual (𝜖) efficiencies (Figure 2.19). For even a modest number of observations 
(N=25), we observed ~0.03 median error in the estimation of efficiency, decreasing to <0.02 for 
datasets with more observations (N=100). Given the average efficiency of simulated NMD in 
each dataset, these errors represent relative estimation errors less than ~5%. 
 
BrainSpan expression data 
We obtained the human brain RNA-Seq expression data from the BrainSpan Atlas of the 
Developing Human Brain (brainspan.org) [84]. We used the BrainSpan project’s developmental 
transcriptome RNA-seq dataset, which includes tables summarizing the average expression level 
in RPKM of human genes and their exons. RPKM values were quantile normalized across 
samples. 
 
Dosage-based model of phenotypic effect 
Human genes likely differ in their contributions to specific phenotypes. Therefore, for 
each gene with multiple LGD mutations in SSC, we estimated the IQ or VABS phenotype’s 
sensitivity to changes in gene dosage (i.e. phenotype dosage sensitivity or PDS). To that end, we 
used least-squares linear regressions, regressing the observed phenotypic effects (𝑦), defined as 
the difference between the average neurotypical scores (100) and the proband’s score, against the 
relative expression of LGD targeted exons c𝑥=!> =
@)*+&
@,)&)
d. In each regression, we assumed that 
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normal (wild type) gene dosage corresponds to a neurotypical score (100) and therefore fixed the 
y-intercept at 0. The slope (𝑠) of the fitted least-squares regression line provided an estimate of 
the phenotypic sensitivity to gene dosage. 
 
Figure 2.20 An illustration of the method we used to estimate phenotypic sensitivity to changes 
in the dosage of a gene. For each gene with multiple truncating mutations in SSC, we used least-squares 
linear regression to estimate the phenotypic sensitivity. We defined phenotypic sensitivity as the slope of 
the fitted regression between the relative expression of the target exon '𝒙𝐞𝐱𝐨𝐧
𝒙𝐠𝐞𝐧𝐞
( and the effect of the 
mutation, i.e. the corresponding proband’s IQ compared to the average neurotypical value (100). Each 
blue point in the figure represents a proband with an LGD mutation in the same gene. The x-axis position 
indicates the relative expression the targeted exon. The y-axis position indicates the observed effect of the 
mutation on IQ. The red line shows the least-squares regression line. 
To express these linear model parameters in terms of gene dosage, we used experimental 
data from GTEx to model the average relationship between the relative expression of an exon 
(𝑥=!>) and the corresponding dosage changes observed due to LGD mutation(s) in that exon. 
These predictions were made by averaging the dosage changes observed for GTEx LGD 
mutations in exons with similar relative expression, defined as values within the 𝛿 half-width 
interval	[𝑥=!> − 𝛿, 𝑥=!> + 𝛿	]. We then averaged the observed dosage changes (Δ𝑥#A1) for GTEx 
mutations in exons with relative expression values within the defined interval. Calculated in that 
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Where 𝑀 is the set of LGD mutations in GTEx in exons with relative expression within 𝜖 of 𝑥=!>. 
The parameter 𝛿 was set to 0.05, which was chosen as the interval width for which estimated 
predicted dosage changes on average had SEM less than 1%. 




the effect of each LGD mutation by the PDS (𝑠) of the affected gene, defined as the expected 
decrease in IQ (or VABS) due to a 10% change in gene dosage. To establish the statistical 
significance of the correlation between normalized phenotypic effects and changes in gene 
dosage, we used a permutation test. Specifically, we reassigned LGD mutations to randomly 
selected exons in the same gene, with the reassignment probability proportional to the length of 
each exon. Then, following the same normalization procedure, we computed the correlation 
between normalized phenotypic effects and relative exon expression in the randomly shuffled 
data. The distribution of the correlations observed in the permuted data was used to estimate 
empirical p-values. 
 
Linear model-based predictions of the effects of LGD mutations 
Based on the dosage sensitivity model described in the previous section, we performed 
leave-one-out predictions of the effect (𝑦) of each LGD mutation on full-scale, nonverbal, and 
verbal IQ, defined as the difference between the observed IQ and the average neurotypical IQ 
(100). To predict the effect of each withheld mutation, we performed least-squares linear 
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regression using all other mutation in the same gene. In each regression, the phenotypic impact 
of mutations was the dependent variable, and the relative expression c𝑥=!> =
@)*+&
@,)&)
d of target 
exons was the independent variable. We assumed that mutations with no effect on gene dosage 
would result in neurotypical IQs and fixed the y-intercept of each regression at 0. The fitted 
regression lines (with slope 𝑠) were used to predict the phenotypic impact of the withheld 
mutation 3𝑦B=!C = 𝑠𝑥=!>7. Prediction errors were calculated as the absolute difference between 
predicted and observed effects 3m𝑦B=!C − 𝑦m7. 
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3 Autism phenotypes and the exon-intron structure of genes 
3.1 Introduction 
In the preceding investigations, we found a substantial correlation between the relative 
expression level of an exon harboring LGD variants and the changes in gene dosage due to 
nonsense-mediated decay (NMD) triggered by those variants. For truncating variants, the 
molecular effects at the transcript level (i.e. dosage loss due to NMD) are understood and, using 
the statistical methods we developed (see Section 2.3), can be quantified using RNA sequencing 
data. We hypothesized that across individuals, (1) consistent patterns of exon usage would lead 
to similar changes in gene dosage for LGD mutations in the same exon; and (2) similar dosage 
changes due to LGD mutations in the same exon would result in similar phenotypic 
consequences. To explore these hypotheses, we studied the phenotypes associated with LGD 
mutations in specific exons. 
In the following results, we considered how the exon-intron structure of genes affects 
multiple important autism phenotypes, such as cognitive ability, adaptive behavior, fine motor 
skills, and coordination. We then investigated the molecular mechanisms potentially underlying 
our findings, including changes in gene dosage due to NMD and changes in the relative 
expression of splicing isoforms. Finally, we explored the relationships between the phenotypic 
consequences of LGD mutations and some functional properties of target exons, including 
position along gene and protein sequences, correspondence to sequences coding for protein 




Exon-specific phenotypes for de novo LGD mutations in ASD 
 We first investigated the variability of cognitive phenotypes associated with de novo 
LGD mutations in the same gene. Consistent with our preliminary analysis (Figure 0.3), we 
found that the average IQ differences between probands with LGD mutations in the same gene 
were only slightly smaller than the IQ differences between all pairs of probands (Figure 3.1). 
Specifically, the mean pairwise differences for probands with mutations in the same gene were: 
28.3 for FSIQ (~11% smaller compared to all pairs of ASD probands, Mann-Whitney U one-tail 
test p = 0.2), 25.7 NVIQ (~12% smaller, p = 0.14), and 34.9 VIQ points (~1.1% smaller, p = 
0.5). 
We next considered the effect of exon-intron structure on IQ phenotypes. Specifically, we 
investigated phenotypes resulting from truncating mutations affecting the same exon in unrelated 
ASD probands; in this analysis, we took into account LGD mutations in the exon’s coding 
sequence as well as disruptions of the exon’s flanking canonical splice sites, since such splice 
site mutations should affect the same transcript isoforms (see Methods Figure 3.26). 
Interestingly, the analysis of 16 unrelated ASD probands (8 pairs with LGD mutations in the 
same exons) showed that they have strikingly more similar phenotypes (Figure 3.1, red bars) 
compared to probands with LGD mutations in the same gene (Figure 3.1, dark green bars); same 
exon FSIQ/NVIQ/VIQ average IQ difference 8.9, 8.3, 17.3 points, same gene average difference 
28.3, 25.7, 34.9 points (Mann-Whitney U one-tail test p = 0.003, 0.005, 0.016). Because of well-
known gender differences in autism susceptibility [5, 85, 86], we also compared IQ differences 
between probands of the same gender harboring truncating mutations in the same exon (Figure 
3.1, orange bars) to IQ differences between probands of different genders; same gender 
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FSIQ/NVIQ/VIQ average difference 5.4, 7.2, 12.2; different gender average difference 14.7, 10, 
25.7 (MWU one-tail test P = 0.04, 0.29, 0.07). Thus, stratification by gender further decreases 
the phenotypic differences between probands with LGD mutations in the same exon.  
 
Figure 3.1 Average difference in IQs between SSC probands. From left to right, the sets of bars 
represent differences between full-scale, nonverbal, verbal IQs. Within each bar set, from right to left, the 
bars represent the average IQ difference between pairs of probands in the entire SSC cohort (light green), 
between probands with de novo LGD mutations in the same gene (dark green), between probands with 
de novo LGD mutations in the same exon (red), and between probands of the same gender and with de 
novo LGD mutations in the same exon (orange). Error bars represent the SEM. 
We extended our analysis to adaptive behavior, measured using the Vineland Adaptive 
Behavior Scales (VABS) [87]. SSC probands with truncating mutations in the same exon 
exhibited more similar adaptive behavior abilities compared to probands with mutations in the 
same gene (Figure 3.2, left set of bars); VABS composite standard score difference of 4.7 versus 
12.1 points (Mann-Whitney U one-tail test p = 0.017). In contrast, VABS differences between 
probands with truncating mutations in the same gene were not significantly different than for 






























All proband pairs in SSC
Proband pairs with LGD mutations in the same gene
Proband pairs with LGD mutations in the same exon
Same gender proband pairs with LGD mutations in same exon
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We also found similar patterns across specific categories of behavior (i.e. communication, 
socialization, and daily living skills) quantified by VABS subscores (Figure 3.3).  
 
Figure 3.2 Vineland Adaptive Behavior Scales (VABS) score differences between probands using 
data from the Simons Simplex Collection (SSC) and the Simons Variation in Individuals Project (VIP). (a) 
Each bar shows the average difference in Vineland composite standard scores between pairs of probands 
in different groups. From right to left, bars represent differences between all pairs of probands in each 
cohort (light green), between probands with LGD mutations in the same gene (dark green), between 
probands with LGD mutations in the same exon (red), and between probands of the same gender with 
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Figure 3.3 Average differences in adaptive behavior scores, i.e. Vineland Adaptive Behavior 
Scales, 2nd ed. (VABS), between probands in SSC. Each bar shows the average difference in VABS scores 
between pairs of probands. From left to right, bar groups represent differences in the composite score, 
and in communication, daily living skills (DLS), and socialization sub-scores. Within each bar group, bars 
represent, from right to left, the average score difference between all pairs of probands in the SSC cohort 
(light green), between probands with de novo LGD mutations in the same gene (dark green), between 
probands with de novo LGD mutations in the same exon (red), and between probands of the same gender 
and with de novo LGD mutations in the same exon (orange). Error bars represent the SEM. 
To validate the observed phenotypic patterns, we analyzed an independently collected 
cohort of ASD probands from the ongoing Simons Variation in Individuals Project (VIP) [29]. 
The analyzed VIP dataset contained genetic information and VABS phenotypic scores for 41 
individuals with de novo LGD mutations in 12 genes. Reassuringly, and consistent with our 
findings in SSC, probands from the VIP cohort with truncating de novo mutations in the same 
exon also exhibited strikingly more similar VABS phenotypic scores compared to probands with 
mutations in the same gene (Figure 3.2, right set of bars; Figure 3.4); VABS composite standard 
score difference 6.0 versus 12.4 (Mann-Whitney U one-tail test p = 0.014). 
Same gender proband pairs with LGD mutations in the same exon
Proband pairs with LGD mutations in the same exon
Proband pairs with LGD mutations in the same gene










































Figure 3.4 Average difference in Vineland adaptive behavior scores between probands in the 
Simons Variation in Individuals Project (VIP). Each bar shows the average difference in Vineland scores 
between pairs of probands. From left to right, bar groups represent differences in the composite standard 
score, and in communication, daily living skills (DLS), and socialization subscores. From right to left 
within each bar group, bars represent the average difference between all pairs of probands in the VIP 
cohort (light green), between probands with de novo LGD mutations in the same gene (dark green), 
between probands with de novo LGD mutations in the same exon (red), and between probands of the 
same gender with de novo LGD mutations in the same exon (orange). Error bars represent the SEM. 
Importantly, the previous analyses describe the variability of individuals’ phenotypes 
across multiple genes. To understand how these effects on phenotypes apply to specific genes, 
for each gene with multiple LGD mutations, we compared the phenotypic differences due to 
LGDs in the same exon and due to LGDs in different exons of the same gene. To obtain more 
statistical power for this analysis, we combined data from SSC and VIP and analyzed VABS 
scores, which were measured in both cohorts. The results demonstrated that phenotypic 
differences for mutations in the same exon were smaller, on average, for 7 out of 8 genes (Table 
3.1). Furthermore, in agreement with other results presented in the paper, a paired statistical test 
across genes demonstrated that ASD phenotypes due to LGDs in the same exons were 
Same gender proband pairs with LGD mutations in the same exon
Proband pairs with LGD mutations in the same exon
Proband pairs with LGD mutations in the same gene









































significantly more similar compared to LGDs in different exons of the same gene (Wilcoxon 
signed-rank one-tail p = 0.012). 
Gene 
LGDs in the same exon LGDs in different exons of the same gene 
Mean N Mean N 
ASXL3 6 3 11.2 15 
CHD2 2 1 18 2 
CHD8 11 1 12.8 20 
DSCAM 1 1 12.5 2 
DYRK1A 0 1 19.8 5 
FOXP1 8.7 3 6.3 3 
HIVEP2 6.7 3 13.7 3 
SCN2A 6.5 2 13.8 14 
P-value P = 0.012, N = 8  
Table 3.1 Vineland (VABS) composite standard score differences between probands with LGD 
mutations in the same or different exons, stratified by gene. For each gene with multiple LGD mutations 
in multiple exons, we calculated the average difference in VABS scores between probands with LGDs in 
the same (left) and different exons (right) of the same gene. To compare effects across genes, we used a 
Wilcoxon signed-rank one-tail test to test whether scores for probands with mutations in the same exon 
were more similar than scores for probands with mutations in different exons of the same gene (Wilcoxon 
signed-rank one-tail p = 0.012). 
Although we primarily focused on cognitive (IQ) and behavioral (VABS) phenotypes, we 
also analyzed several other important ASD phenotypes. We reasoned that the hypothesized 
underlying mechanisms – i.e. similar dosage changes from LGD mutations in the same exon – 
should lead to analogous results for other quantitative ASD phenotypes [24, 46]. Indeed, for 
LGD mutations predicted to lead to NMD, we observed similar patterns for several other key 
autism phenotypes. Probands with truncating mutations in the same exon displayed more similar 
fine motor skills; in the Purdue Pegboard Test, 1.2 versus 3.0 for the average difference in 
normalized tasks completed with both hands (MWU one-tail test P = 0.02; Figure 3.5; see 
Methods). Coordination scores in the Social Responsiveness Scale questionnaire were also more 
similar in probands with LGD mutations in the same exon compared to probands with mutations 
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in the same gene; 0.6 versus 1.1 for the average difference in normalized response (MWU one-
tail test P = 0.05; Figure 3.6). 
 
Figure 3.5 Average difference in Purdue Pegboard Test scores between pairs of ASD probands. 
From left to right, bar groups represent Purdue Pegboard Test scores for both hands, for the dominant 
hand, and for the non-dominant hand. Within each bar group, bars represent, from right to left, the 
average difference between all pairs of probands in SSC (light green), between pairs of probands with de 
novo LGD mutations in the same gene (dark green), and between pairs of probands with LGD mutations 
in the same exon (red). Purdue Pegboard scores were adjusted to account for probands’ age and gender 
(see Methods). The statistical significances were calculated using Mann-Whitney U tests (PMWU). Error 
bars represent the SEM. 
PMWU = 0.02 PMWU = 0.09 PMWU = 0.18
PMWU = 0.4 PMWU = 0.8 PMWU = 0.2
All proband pairs in SSC
Proband pairs with LGD mutations in the same gene











































Figure 3.6 Average difference in Social Responsiveness Scales (SRS) coordination score between 
ASD probands. The bars represent, from right to left, all pairs of probands in SSC (light green), pairs of 
probands with de novo LGD mutations in the same gene (dark green), and between pairs of probands 
with LGD mutations in the same exon (red). SRS scores were adjusted to account for probands’ age and 
gender (see Methods). The statistical significance was determined using Mann-Whitney U tests (PMWU). 
Error bars represent the SEM. 
We then investigated the relationship between background genetic variation in 
individuals and the phenotypic effects of de novo LGD mutations in specific exons. Accordingly, 
we separately analyzed probands from trio families (i.e. families without unaffected siblings). In 
these probands, the enrichment of LGD mutations is likely to be substantially lower, and the 
contribution from genetic background larger [88]. Interestingly, when affected by LGD 
mutations in the same exon, probands from sequenced trio families varied significantly (~2 
times) more in IQ phenotypes than probands from quad families (Figure 3.7), suggesting that 
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Figure 3.7 Average IQ differences between SSC probands from quad and trio ASD families. 
Quad families have a single affected child among with one or multiple unaffected; trio families have an 
affected child with no siblings. From left to right, differences are shown for full-scale IQ (FSIQ), 
nonverbal IQ (NVIQ), and verbal IQ (VIQ) scores. For each score, bars represent the average IQ difference 
between probands with de novo LGD mutations in the same gene (dark green), between pairs of probands 
with mutations in the same exon and with at least one proband from a trio family (light green), and 
between probands from quad families with mutations in the same exon (purple). The statistical 
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As a negative control, we analyzed probands with synonymous mutations in the same 
exon. Reassuringly, such probands were as phenotypically diverse as random pairs of probands 
(FSIQ, NVIQ, VIQ Mann-Whitney U on-tail test p = 0.93, 0.97, 0.95; Figure 3.8). Interestingly, 
when we analyzed missense mutations in the same exon, we also did not see a significant 
decrease in variability between affected probands (MWU one-tail test p = 0.8, 0.5, 0.8; Figure 
3.9), potentially because their effects on protein stability and function may significantly vary 
within the coding sequence of a single exon. These results suggest that the underlying 
mechanisms that explain our observations are specific to LGD mutations. 
 
Figure 3.8 The average differences in IQ between probands with synonymous mutations in the 
same gene or the same exon. Each bar represents the average IQ difference between all pairs of probands 
in the SSC cohort (light green), between pairs of probands with synonymous mutations in the same gene 
(dark green), and between pairs of probands with synonymous mutations in the same exon (red). From 
left to right, sets of bars represent differences for full-scale, nonverbal, and verbal IQs. Error bars 
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Figure 3.9 Average difference in IQ between probands with missense mutations in the same 
gene or the same exon. Each bar represents the average IQ difference between all pairs of probands in the 
SSC cohort (light green), between pairs of probands with missense mutations in the same gene (dark 
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Exon-specific gene- and isoform-level dosage changes due to LGD variants 
To explain the similarity of phenotypes resulting from LGD mutations in the same exon, 
we hypothesized that truncating mutations in the same exon usually affect, due to nonsense-
mediated decay (NMD) [64], the expression of exactly the same sets of splicing isoforms. 
Therefore, such mutations should lead to similar phenotypes, both through similar decreases in 
overall gene dosage and similar perturbations to the relative expression of the same 
transcriptional isoforms. To evaluate this mechanistic model, we used data from the Genotype 
and Tissue Expression (GTEx) Consortium [76, 77], which collected exome sequencing and 
corresponding human tissue-specific gene expression data from hundreds of individuals and 
across multiple tissues. Using ~4,400 LGD variants in coding regions and corresponding RNA-
seq data, we compared the expression changes resulting from LGD variants in the same and 
different exons of the same gene (Figure 3.10). Specifically, for each truncating variant, we 
analyzed allele-specific read counts [65] and then developed and used a novel empirical Bayes 
approach to estimate the effects of NMD on gene expression (see Chapter 2).  
This analysis confirmed that the average gene dosage changes for individuals with LGD 
variants in the same exon were ~7 times more similar compared to individuals with LGD 
variants in different exons of the same gene (Figure 3.10a); 2.2% versus 17.3% average 
difference in the decrease of overall gene dosage (Mann-Whitney U one-tail test p ˂ 2×10-16). 
Moreover, by analyzing GTEx data for each human tissue separately, we found that, across all 
tissues, LGD variants in the same exons led to drastically more similar dosage changes of target 





Figure 3.10 Gene expression changes across human tissues due to LGD variants in the same 
exon and in the same gene but different exons. Expression changes (decreases) due to LGD variants were 
calculated based on data from the Genotype and Tissue Expression (GTEx) Consortium. (a) Bars 
represent the average difference across the GTEx cohort in overall gene expression changes induced by 
distinct LGD variants in the same exon (red) and in the same gene but different exons (blue). Error bars 
represent the SEM. (b) Bars represent the average difference across the GTEx cohort in isoform-specific 
expression changes induced by distinct LGD variants in the same exon (red) and in the same gene but 
different exons (blue). Differences in expression changes across transcriptional isoforms were quantified 
using the angular distance metric between vectors representing isoform-specific expression changes (see 
Methods). Error bars represent the SEM. 
Distinct splicing isoforms have different functional properties [89, 90], and based on our 
previous analyses, we hypothesized LGD variants may affect phenotypes not only through 
NMD-induced changes in overall gene dosage, considered above, but also by altering the relative 
expression levels of all isoforms in a similar way. To analyze changes in the relative expression 
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gene. To compare isoform-specific expression changes in the same gene, we calculated an 
angular distance metric between vectors representing dosage changes for each isoform (see 
Methods). This analysis demonstrated that changes in relative isoform expression are also 
significantly (~5 fold) more similar for LGD variants in the same exon compared to variants in 
different exons of the same gene (Figure 3.10b); 0.1 versus 0.46 for the average angular distance 
between isoform-specific expression vectors (Mann-Whitney U one-tail test p < 2×10-16). These 
results were also consistent across tissues (Figure 3.10b). Overall, the analyses of GTEx data 
demonstrate that both overall changes in gene dosage and changes in the relative expression 
levels of different isoforms are substantially more similar for truncating mutations in same 
exons. 
 We sought to further confirm our results using in vitro experimental measurements. To 
that end, we used data from a previously published CRISPR/Cas9-based genetic editing 
experiment in HAP1 cell lines [67, 68]. In the experiment, nearly all possible single nucleotide 
variants (~3,900 SNVs) were introduced across entire sequences of target exons in the BRCA1 
gene. The effect of each LGD mutation on gene dosage was calculated by estimating the mRNA 
expression level for each cell affected by the LGD mutation. In our analysis, we found that gene 
dosage varied approximately twice as much for LGD mutations in different exons versus LGD 
mutations in the same exon; 0.17 versus 0.32 mean difference in dosage due to mutations in the 
same exon and different exons, respectively; Mann-Whitney U one-tail test p < 2.2×10-16 (Figure 
3.11). These results experimentally validated our analyses of GTEx expression data and were 




Figure 3.11 Differences in the effects of NMD between LGD mutations in the same exon and 
LGDs in the same gene (BRCA1), but not necessarily the same exon. Bars represent pairs of LGD 
mutations in the same exon and pairs of LGD mutations in the same gene. The y-axis represents the 
average difference in dosage change between LGD mutations in the same exon or the same gene. Change 
in dosage due to NMD were calculated by comparing the expression level of BRCA1 for cells with LGD 
mutations to the average expression level for cells with synonymous mutations. Annotations represent 
the Mann-Whitney one-tail test p-value. Error bars represent the SEM. 
 Given the strong selective pressure against LGD mutations in exons with higher relative 
expression, we then asked, at the population level, if exons expressed at similar levels would 
have similar intolerance to LGD mutations. To investigate, we used ultra-rare (UR) variants, 
defined as variants observed only once in a sequenced population, in the Exome Aggregation 
Consortium (ExAC) dataset to estimate the intolerance of exons to LGD mutations. Specifically, 
we calculated for each exon the ratio of UR LGD variants to UR synonymous variants. When we 
compared differences in the percent usage of exons and the intolerance of exons to LGD 
variants, we indeed found that different exons with similar usage indeed had similar intolerance 



















































differed less than 10% in three times less variability (0.05 vs. 0.15) in intolerance compared to 
exons with differences in usage >50%. 
 
Figure 3.12 Similarity in intolerance to LGD mutations for exons with similar dosage. For each 
pair of exons in a gene, we compared their differences in usage (calculated as the absolute difference in 
percent spliced-in or PSI) and their intolerance to LGD mutations. The x-axis represents the difference in 
PSI between exons; from left to right, points represent comparisons between exons with increasing 
differences in usage. The y-axis represents the average difference in intolerance score between exons. 
Intolerance scores were defined as the ratio of ultra-rare (UR), i.e. observed only once in a sequencing 
population, LGD variants to UR synonymous variants in the exon. Error bars represent the SEM. 
 We then used exons’ intolerance to LGD variation to estimate the relative contributions 
to evolutionary selection of overall gene-level dosage changes versus changes in the relative 
expression of isoform. When we compared intolerance scores between exons affecting exactly 
the same isoforms versus exons with similar dosage but affecting different isoforms, we found 
that the similarity in usage explained 45% of the variability in selection across exons, while the 
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Figure 3.13 Relative contributions of gene- and isoform-level dosage changes to exon 
intolerance. From left to right, points represent the difference in intolerance score between exons in the 
same gene, between exons in the same gene with similar percent spliced-in (difference in PSI £ 0.1), and 
between exons spliced into exactly the same transcriptional isoforms. Intolerance scores were defined as 
the ratio of ultra-rare, i.e. observed only once, LGD variants to UR synonymous variants in the ExAC 
dataset. Values were normalized to the average difference in scores within an exon. Error bars represent 
the SEM. 
 
Phenotypic consequences of LGD mutations across gene and protein sequences 
 Given the similarity of phenotypes resulting from LGD mutations in the same exon, we 
investigated whether LGD mutations in neighboring exons would also produce similar 
phenotypes. Notably, the patterns of phenotypic similarity between probands only extended to 
mutations in the same exon. The average IQ differences between SSC probands with LGD 
mutations in neighboring exons were not significantly different compared to mutations in non-
neighboring exons (MWU one-tail test p = 0.6, 0.18, 0.8; Figure 3.14). Similarly, in the 
independent VIP cohort, LGD mutations in neighboring exons also did not result in more similar 
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behavior phenotypes (VABS composite standard score average difference 13.6 points; MWU 
one-tail test p = 0.6) than LGD mutations in the same gene. 
 
Figure 3.14 The average IQ differences between probands with LGD mutations in the same 
exon, in neighboring exons of the same gene, and in non-neighboring exons of the same gene. Plots 
represent (a) full-scale IQ (FSIQ), (b) nonverbal IQ (NVIQ), and (c) verbal IQ (VIQ) scores. Each overlaid 
point represents a pair of probands with LGD mutations in the same exon, in neighboring exons, or in 
non-neighboring exons. The y-axis represents the IQ difference between affected probands. The statistical 
significance was determined using Mann-Whitney U tests (PMWU). Error bars represent the SEM. 
 To understand more generally how the proximity of LGD mutations affects proband 
phenotypes, we asked whether LGD mutations at similar locations in gene sequence were 
associated with more similar proband phenotype (Figure 3.15). Consistent with our exon-level 
findings, IQ differences between probands with LGD mutations closer than 1000 base pairs apart 
were indeed significantly smaller than the IQ differences between probands with more distant 
mutations; ≤1 kbp FSIQ/NVIQ/VIQ average difference 11.5, 10.4, 20.6 points; >1 kbp average 
difference 31.4, 28.6, 37.5 points (MWU one-tail test p = 0.002, 0.005, 0.01). However, across 
the entire range of nucleotide distances between LGD mutations in the same genes, we did not 
observe either a significant correlation or a monotonic relationship between IQ differences and 
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mutation proximity (FSIQ/NVIQ/VIQ Spearman’s 𝜌 = 0.09, 0.1, 0.03, p = 0.5, 0.4, 0.8; one-tail 
Mann-Kendall test p = 0.5, 0.3, 0.6). 
 
Figure 3.15 IQ differences between pairs of probands with de novo LGD mutations in the same 
gene. Each point in the figures corresponds to a pair of probands from the SSC cohort with de novo LGD 
mutations in the same gene. The x-axis represents the nucleotide distance between LGD mutations. The 
y-axis represents the absolute difference in IQs (full-scale, nonverbal, or verbal IQ) between affected 
probands. Moving averages are shown in red. 
We next explored the relationship between phenotypic similarity and the proximity of 
truncating mutations in the corresponding protein sequences. This analysis revealed that 
probands with LGD mutations in the same exon often had similar IQs, despite being affected by 
truncating mutations separated by scores to hundreds of amino acids in protein sequence (Figure 
3.16). Furthermore, we found probands with LGD mutations in the same exon to be more 
phenotypically similar than probands with LGD mutations separated by comparable amino acid 
distances in the same protein sequence but not necessarily in the same exon (FSIQ/NVIQ/VIQ 


































































































































































































































Figure 3.16 Amino acid distance between LGD mutations in protein sequence versus the IQ 
differences between corresponding probands. From left to right, plots show differences in (a) full-scale IQ 
(FSIQ), (b) nonverbal IQ (NVIQ), and (c) verbal IQ (VIQ) scores. Each point in the figures corresponds to 
a pair of probands affected by de novo LGD mutations in the same gene. The x-axis represents the amino 
acid distance between LGD mutations, and the y-axis represents the absolute difference between the 
probands’ IQs. Open (white) points correspond to pairs of probands with LGD mutations in different 
exons of the same genes; filled (colored) points correspond to pairs of probands with mutations in the 
same exon of the same genes. 
 
Figure 3.17 Simulated null distributions of the average IQ difference between probands with de 
novo LGD mutations in the same gene and with similar distances in the corresponding protein sequence. 
From left to right, histograms show the distribution of average differences for (a) full-scale IQ (FSIQ), (b) 
nonverbal IQ (NVIQ), and (c) verbal IQ (VIQ) scores across the sampled null distribution trials 
(N=10,000). The histograms show the null trial frequencies of the average IQ differences (x-axes) between 
pairs of probands with mutations in the same gene, where mutations were separated by amino acid 
distances similar to the ones empirically observed between LGD mutations in the same exon (see 
Methods). The red dashed lines represent the observed average IQ differences between probands with 
LGD mutations in the same exon. 
(a) (b) (c)
P = 0.010 P = 0.002 P = 0.018












































Using data from both SSC and VIP, we similarly investigated whether the similarity of 
VABS scores was due to the presence of mutations in the same exon, rather than proximity of 
truncating mutations within the corresponding protein sequence. Indeed, LGD mutations in the 
same exon often resulted in similar adaptive behavior abilities even when the corresponding 
mutations were separated by hundreds of amino acids (Figure 3.18). By comparing mutations in 
the same exon to mutations separated by similar amino acid distances in the same protein but not 
necessarily the same exon, we confirmed that probands with mutations in the same exon were 





Figure 3.18 Amino acid distance between LGD mutations in the same protein versus the 
differences in Vineland (VABS) score between probands; data from the SSC and VIP cohorts were 
combined. Clockwise from top left, plots show differences in VABS (a) composite standard score, and (b) 
communication, (c) daily living skills (DLS), and (d) socialization subscores. In the figures, each point 
corresponds to a pair of probands affected by de novo LGD mutations in the same gene. The x-axis 
represents the amino acid distance between LGD mutations, and the y-axis represents the difference 
between the affected probands’ VABS scores. Open (white) points correspond to proband pairs with 
mutations in different exons of the same gene; filled (colored) points correspond to pairs with mutations 




Figure 3.19 Simulated null distributions of the average Vineland (VABS) score difference 
between ASD probands (from the combined SSC and VIP cohort) with de novo LGD mutations in the 
same gene and separated by similar distances in corresponding protein sequence. Clockwise from top 
left, histograms represent the distribution of average differences in VABS score for (a) the composite 
standard score, and for the (b) communication, (c) daily living skills (DLS), and (d) socialization 
subscores. Each value in the histogram represents the average Vineland score difference between pairs of 
probands with mutations in the same gene and with protein amino acid distances similar to the distances 
empirically observed for LGD mutations in the same exon (see Methods). The red dashed lines represent 
the observed average score differences between probands with mutations in the same exon. 
We also investigated whether de novo mutations truncating a larger fraction of protein 
sequences resulted, on average, in more severe phenotypes. Surprisingly, this analysis showed no 
significant correlations between the fraction of truncated protein and the severity of intellectual 
phenotypes (FSIQ/NVIQ/VIQ Pearson’s R = 0.05, 0.05, 0.06; p = 0.35, 0.35, 0.28; Figure 3.20). 
Across both SSC and VIP, the fraction of truncated proteins also did not show significant 
correlation with the VABS scores of affected probands (Pearson’s R = -0.08, p = 0.7). We also 
did not find any significant biases in the distribution of truncating de novo mutations across 
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protein sequences compared with the distribution of synonymous de novo mutations 
(Kolmogorov-Smirnov two-tail test p = 0.9; Figure 3.21). It is possible that the lack of the 
correlation between phenotypic impact and the fraction of truncated sequence is due to the 
averaging of effects across many proteins with diverse functions. Therefore, for genes with 
recurrent mutations, we used a paired test to investigate whether truncating a larger fraction of 
the same protein sequence led to more severe phenotypes. This analysis also showed no 
substantial phenotypic difference due to LGD mutations truncating different fractions of the 
same protein (average NVIQ difference 0.24 points; Wilcoxon signed-ranked one-tail test p = 
0.44). 
 
Figure 3.20 Relative fraction of protein sequence truncated by LGD mutations versus proband 
IQs. Each point corresponds to a single proband in SSC affected by an LGD mutation. From left to right, 
the plots show (a) full-scale IQ (FSIQ), (b) nonverbal IQ (NVIQ), and (c) verbal IQ (VIQ) scores. The x-axis 
represents the fraction of protein amino acid sequence (i.e. fraction from the first amino acid) truncated 
by the LGD mutation. The y-axis represents the corresponding proband’s IQ score. Red lines represent 


































































Figure 3.21 Cumulative distributions of the relative amino acid positions of de novo LGD 
mutations. Each line represents the cumulative distribution of the relative protein sequence positions (i.e. 
fraction of the total sequence length from the first amino acid) for LGD mutations in genes with multiple 
truncating mutations in SSC (red), for all LGD mutations in SSC (orange), and for synonymous mutations 
in unaffected siblings in SSC (blue). 
 
Phenotypic consequences of LGDs affecting functional coding sequences 
Mutations close to each other in protein sequence, such as mutations in the same exon, 
are likely to affect the same protein domains. To separate the effect of losing similar domains 
from the effect of targeting the same exon, we used the Pfam database [91] to identify mutations 
truncating the same protein domain (see Methods Figure 3.27). Mutations in different exons, 
even when truncating the same protein domain, resulted in very different phenotypes, i.e. 
phenotypes as different as due to two random LGD mutations in the same gene (Figure 3.22). 
We observed consistent results for both IQs (average NVIQ difference = 28.1; Figure 3.22a) and 




Figure 3.22 Average phenotypic differences between probands with LGD mutations truncating 
the same protein domain. Bars represent the average difference in (a) nonverbal IQ or (b) Vineland 
composite standard scores between pairs of probands with LGD mutations affecting: the same gene (dark 
green); different exons, but truncating the same domain (grey); or the same exon (red). Error bars 
represent the SEM. 
We also investigated whether mutations that truncate more protein domains lead to more 
severe phenotypes. Interestingly, for both NVIQ and VABS composite scores, we found no 
significant correlation between phenotype severity and the number of protein domains lost due to 
truncating mutations (NVIQ Pearson’s R = -0.054, Spearman’s r = 0.016; VABS Pearson’s R = 
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Figure 3.23 Relationship between number of domains lost due to LGD mutations and proband 
phenotypes. Boxplots represents the distribution of (a) nonverbal IQ or (b) Vineland (VABS) scores for 
probands affected by LGD mutations. Within each panel, from left to right, probands are grouped by 
increasing number of protein domains truncated by LGD mutations. Lines in the middle of each box 
represent median scores, the top and bottom of each box represents the 25th and 75th percentiles 
respectively, and the whiskers represent the 5th and 95th percentiles. Outliers, defined as values more 
than 1.5 IQRs from the median, are plotted as individual points. 
Different splicing isoforms of a gene can have different functional properties [89, 90]. 
Moreover, even genes with dozens of isoforms express a dominant isoform that captures a large 
fraction (>30%) of total gene expression [92]. Consequently, we investigated whether the 
similarity of phenotypes resulting from LGD mutations in the same exon could be attributed to 
truncation of a single, functionally important isoform. By using the APPRIS database to identify 
major isoforms [93], we found that LGD mutations affecting a common major isoform led to 
significantly higher (2-3 times) phenotypic diversity compared to mutations in the same exon 
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not just affect a single isoform, but affect, in a similar way, the whole set of isoforms containing 
the target exon. 
 
Figure 3.24 IQ differences between pairs of probands with mutations affecting the same 
principal isoform of a gene. Each bar represents the average difference in IQ between pairs of probands 
with LGD mutations: in the same gene (dark green), in the same major isoform (grey), or in the same 
exon (red). Major isoforms for each gene were identified using the APPRIS database. Error bars represent 
the standard error of the mean. 
To understand the phenotypic consequences of mutations affecting multiple common 
isoforms, we calculated the correlation between probands’ phenotypic similarity and the fraction 
of shared isoforms that are affected by the mutations. We note that our current knowledge of 
major human gene isoforms is quite incomplete. Despite this, based on isoform annotations in 
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and similarity of NVIQ and VABS phenotypes; Spearman’s R = -0.21, -0.19; p = 0.02, 0.006; for 
NVIQ and VABS, respectively.  
 We then investigated whether the phenotypic consequences of an LGD mutation in an 
exon could be explained by its evolutionary conservation. To that end, we correlated the 
evolutionary conservation of exons harboring LGD mutations with the IQ phenotypes of the 
affected probands. Using several different measures of evolutionary conservation, including 
GERP scores [94], PhyloP [95], and PhastCons [96], we found relatively weak correlations 
between the conservation of the exon and the probands’ IQs (NVIQ versus 
GERP/PhyloP/PhastCons scores, Pearson’s R = -0.13, -0.14, -0.03; Figure 3.25). Thus, 
differences in the evolutionary conservation of target exons can explain at most ~1-2% of the 




Figure 3.25 Evolutionary conservation of exons versus proband IQ phenotypes. Each point in 
the scatterplots represents an SSC proband affected by an LGD mutation. In each panel, the x-axes 
represent the evolutionary conservation of exons harboring LGD mutations. Evolutionary conservation 
was quantified (from left to right columns) using GERP, phyloP, or PhastCons scores. The y-axes 
represent (from top to bottom rows) the full-scale, nonverbal, or verbal IQ score for probands affected by 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































Genetic and phenotypic data 
We used exome sequencing and phenotypic data available in the Simons Simplex 
Collection (SSC) [28]. Specifically, de novo LGD mutations were obtained from Iossifov et al. 
[8], and phenotypic data were obtained from Prepared Phenotype Dataset (v15) available through 
the SFARI Base online data portal (sfari.org/resources/sfari-base). From the Simons Variation in 
Individuals Project (VIP) [29], we analyzed de novo LGD mutations and and phenotypes the 
Simons VIP Phase 2 Single Gene Dataset v4.0, also available on SFARI Base. 
 
Normalization of phenotypic scores 
SSC and SVIP include ASD probands of both genders spanning a broad range of ages 
and phenotypic abilities. While some phenotypes, such as IQ and VABS scores, are already 
normalized based on gender and age, other phenotypes are provided as raw scores that vary with 
the age and/or gender of the proband. To account for the effects of age and gender, we adjusted 
raw scores for such unnormalized phenotypes. Following an approach previously used by Buja, 
et al. [97], we adjusted phenotypic scores using linear regression. Specifically, using phenotypic 
scores from all probands, we performed a multivariate linear regression for each raw score, with 
age and gender as independent regression parameters. We used a binary variable (taking value 0 
for male or 1 for female) to capture mean differences across genders. We then used the 
regression residuals as adjusted scores for comparing proband phenotypes. 
Notably, while the SSC and VIP datasets does not provide the exact age of probands at 
the time when each specific phenotype was collected, we approximated the probands’ ages by 
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using the age at which the Autism Diagnostic Observation Schedule was administered (database 
column “age at ADOS”).  
 
Registration of splice site mutations to exons 
 To study the effects of exon-intron structure, we considered LGD mutations, including 
nonsense, frameshift, and splice site mutations, either in the same exon or in different exons of a 
a target gene. Splice site mutations, which affect intronic sequences, were assigned to the 
adjacent exon, rather than the target intron. Such splice site mutations should affect the same 
transcript isoforms as coding sequence mutations in the flanked exon (Figure 3.26). 
 
Figure 3.26 Illustration showing an example of LGD mutations affecting either of two 
transcriptional isoforms of a gene. Exons are represented by blue rectangles, their flanking canonical 
splice sites by light blue boxes, and splicing patterns by diagonal lines joining the corresponding splice 
sites. Loss-of-function mutations in the exon’s coding sequence (black arrows) and mutations disrupting 
the exon’s flanking canonical splice sites (red arrows) usually affect the same transcriptional isoforms. 
 
Comparison of phenotype variability 
To compare phenotypes between probands, we computed the absolute difference in 
scores (IQ, VABS, etc.) between pairs of individuals. We paired probands based on whether or 
not they are affected by similar LGD mutations. Specifically, we compared pairs of probands: (1) 
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with LGD mutations in the same gene, (2) with mutations in the same gene and within 1000 bp, 
(3) with mutations in the same exon, and (4) with mutations in the same exon and of the same 
gender. For each group of paired comparisons, we estimate the phenotypic variability by 
calculating the average absolute difference in scores across all pairs. To estimate the statistical 
significance of differences in phenotypic variability, we then used one-tailed Mann-Whitney U 
tests to compare pairwise differences. 
 
Chromosomal distance between mutations 
We computed the distance in base pairs between a pair of mutations in the same gene by 
taking the absolute difference between their chromosomal positions. For deletion mutations that 
affect a genomic interval (i.e. deletion of multiple base pairs), we used the chromosomal 
coordinates that lead to the smallest distance between mutations. For example, the distance 
between a deletion and an upstream mutation was calculated based on the 5’ coordinate of the 
deleted sequence, while the distance to a downstream mutation was calculated based on the 3’ 
coordinate. Our results remained essentially unchanged when alternate distance metrics, such as 
interval midpoints or maximal distances, were used (results not shown). 
 
Protein sequence analyses 
To calculate the position of ASD mutations in protein sequence, we mapped genomic 
coordinates onto their respective protein-coding sequences. Gene annotation data, including both 
genomic coordinates and the corresponding coding sequence intervals, were obtained from the 
Ensembl database using the BioMart interface (biomart.org) [98]. Using primary amino acid 
sequences for each protein, we mapped each LGD mutation to a resulting premature stop codon 
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in protein sequence We calculated (1) the distance between induced stop codons in amino acid 
sequence and (2) the fraction of protein sequence truncated by each premature stop codons. We 
then calculated the correlation between the fraction of protein sequence affected (truncated) and 
the corresponding proband phenotype. The analysis of correlations between relative amino acid 
positions and IQ phenotypes includes a small number of variants from X/Y chromosomes (~2% 
of all variants). Very similar results are obtained when these variants are excluded from the 
analyses. 
Due to alternative splicing, the peptide distance between mutations can vary across 
transcript isoforms. In the analyses presented in the paper, we analyzed the mean peptide 
distance across all isoforms. However, we also used other definitions of distance, including: the 
maximal distance, the distance in the longest transcript isoform of the gene (or “canonical” 
isoform), or the median distance. Our results were consistent across different measures of 
peptide distance. 
 
Distance-matched permutation tests 
We performed a test in which we controlled for the peptide-sequence proximity of 
mutations in the same exon. To produce random pairs of mutations with peptide distances similar 
to those observed for mutations in the same exon, we used a rejection sampling approach. The 
motivation for this approach was that we were able to easily sample pairs of mutations in the 
same gene (by randomly choosing observed pairs of mutations). However, we wanted the 
peptide distances between mutations to match a distance distribution similar to the distances 
between mutations in the same exon. 
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Thus, we calculated two log-normal peptide distance distributions: a target distribution 
𝑡(𝑑) (mean: 1.89, SD: 0.55) describing the distribution of distances between mutations in the 
same exon, and a sampling distribution 𝑠(𝑑)  (mean: 2.50, SD: 0.54) describing the distribution 
of distances between mutations in the same gene, but not necessarily the same exon. Then, for a 
randomly selected pair of mutations sampled with replacement, we accepted it as a null 





Where 𝑚 is a constant that bounds the likelihood ratio between the distributions. The resulting 
rejection sampling algorithm generates samples approximating the target distribution 𝑡(𝑑) using 
proposals from the sampling distribution 𝑠(𝑑). 
We then estimated the statistical significance of our results by comparing the observed 
differences in IQ to those observed for distance-matched sets of mutations in the null 
distribution. 
 
Identifying protein domains affected by LGD mutations 
 To identify functional domains in proteins affected by LGD mutations, we downloaded 
domain annotations from the Pfam database [91]. We matched Uniprot accession codes to 
register premature truncating codons (introduced into genes by LGD mutations) onto each 
annotated protein sequence (Figure 3.27). We then identified LGD mutations truncating the same 
domain of a protein. In this analysis, we assumed that both complete loss and partial truncation 





Figure 3.27 Illustration of mapping LGD mutations in SSC onto affected protein. Each bar 
diagram represents an example protein sequence (for SCN2A and DYRK1A), where subscript numbers 
represent coordinates in primary amino acid sequence. Colored boxes along the length of each sequence 
represent protein domains. Blue points represent LGD mutations in SSC mapped onto the corresponding 
protein sequence. Domains were identified using the Pfam database. 
 
Enrichment of mutations in developmentally biased exons 
For each exon in BrainSpan, we calculated the developmental bias statistic, defined as the 
difference between mean prenatal and mean postnatal expression levels. Means were calculated 
for log-transformed values (log2 x+1) across all prenatal or postnatal samples. Only exons 
expressed in the brain were considered (average RPKM ³1). Exons from genes harboring LGD 
mutations were partitioned into quartile groups based on developmental bias. Enrichment in each 
exon group was calculated by comparing the fraction of LGD mutations affecting the grouped 
exons with the fraction of coding DNA sequences contained in the exons. Coding sequence 




LGD mutations mapped onto Pfam domains
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Analysis of NMD induced by LGD variants in GTEx 
In our analysis of GTEx data, we used our previously developed empirical Bayes model 
to calculate the percent of wild-type gene expression lost (Δ𝑥=!>) due to each LGD variant in 
GTEx. We then compared 𝛥𝑥=!> either between pairs of variants in the same exon or in the same 
gene but different exons. 
 
Isoform-specific expression changes due to LGD variants 
To quantify the effect of LGD variants on different splicing isoforms of a gene, we used 
our previously developed empirical Bayes model to calculate the change in expression separately 
for each transcriptional isoform of a gene. Importantly, we adapted our calculations to use RNA 
sequencing data summarized to isoform-specific expression levels. To that end, we introduced an 
indicator random variable (𝑰), defined for each of k isoforms, which takes value 1 if an isoform 





To apply our model, we defined the observed expression level of the exon harboring an LGD 
mutation (𝑥′!"#$ in Eqn. 2) as the sum of expression levels across all isoforms in a gene that are 
contain the affected exon, i.e. 
𝑥′!"#$ = j 𝑰H𝑥′H
I1#J#=E	H
						(13) 
Where k indexes the isoforms of a gene and 𝑥′H is the measured expression of the isoform. Then,  
analogous to our calculation for changes in the overall expression of a gene (see Eqn. 1), we 




𝑓 ⋅ 𝜖 ⋅ 𝑥I1#J#=E	H if	isoform	𝑘	contains	affected	exon
0 otherwise
							(14) 
Which, using Equation 12, can be expressed more concisely as: Δ𝑥H = 𝑰H ⋅ 𝑓 ⋅ 𝜖 ⋅ 𝑥H. 
To compare the effects of LGD mutations across n protein-coding isoforms of a gene, we 
represented the overall profile of all isoform expression changes as an n-dimensional vector: 
𝑧̅ = (𝛥𝑥I1#J#=E	,, ⋯ , 𝛥𝑥I1#J#=E	H , ⋯ , 𝛥𝑥I1#J#=E	K)							(15) 
To quantify the difference between isoform-specific expression change vectors, we used an 




M, 𝑧,̅ ∘ 𝑧L̅
‖𝑧,̅‖L ⋅ ‖𝑧L̅‖L
										(16) 
The dot ( ∘) operator in the numerator represents the dot product between vectors. The 
denominator is the scalar product of the ℓL (Euclidean) norms for each vector. In this way, the 
distance 𝑑, which takes values on the unit interval [0,1], computes a normalized angle between 
the expression change vectors for LGD variants. As with total gene expression in the manuscript, 
we compared the distances d either between pairs of variants in the same exon or in the same 
gene but different exons. 
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4 Properties of exons and genes harboring LGD mutations in ASD 
4.1 Introduction 
 Prior studies, including our previous work, analyzed important functional properties of 
genes with LGD mutations in ASD. For example, we and others identified common biological 
functions shared by target genes, expression biases towards specific cell types (including cortical 
neurons and striatal medium spiny neurons), and the widespread expression of ASD-associated 
genes throughout the human brain. These results have now been validated in multiple subsequent 
analyses. To our knowledge, however, no previous studies have investigated functional 
properties at the level of exons harboring autism-associated LGD mutations. Nor have previous 
studies connected functional properties of mutations, such as developmental expression or cell 
type-specific expression, to autism phenotypes in affected individuals. Building on previous 
work, we explored the functional properties of both target exons and genes and the relationships 
between such properties and ASD phenotypes. 
 Given the importance of exons in determining the phenotypic consequences of LGD 
mutations, in the presented studies we sought to characterize the expression-level properties of 
exons harboring LGD mutations in ASD. Specifically, we considered the expression level of 
target exons relative to other exons in the same gene, as well as changes in the expression of 
target exons across human development. We further investigated whether and to what extent 
probands’ IQ phenotypes are associated with the identified patterns of exon expression. 
 We also performed a broad analysis of cell types in the brain that are likely to be affected 
by mutations in ASD. Specifically, we used recent large-scale single-cell sequencing datasets to 
implicate several novel cell types, including previously inaccessible neuronal populations and 
cells from novel brain regions. Based on these findings, we then considered possible correlations 
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between mutations affecting implicated cell types and the phenotypic consequences observed in 
affected probands. Finally, we investigated the relationship, in terms of phenotypic variance 





Developmental expression of exons harboring LGD mutations 
Given that relative exon usage varies across neural development [69, 99] and the strong 
association between exons and phenotypes, we explored how the developmental expression of 
exons relate to ASD phenotypes. To that end, we sorted exons from genes harboring LGD 
mutations [8] into four quartile groups based on their developmental expression bias, which was 
calculated as the fold-change between prenatal and postnatal exon expression levels (Figure 
4.1a). We then analyzed the enrichment of LGD mutations in each exon group (see Methods). 
Compared to exons with no substantial developmental bias, we found significant enrichment of 
LGD mutations not only in exons with a strong prenatal bias (binomial one-tail test p = 8×103, 
Relative Rate = 1.33), but also in exons with postnatal biases (p = 0.018, RR = 1.31) (Figure 
4.1b). 
To understand the phenotypes associated with these patterns of expression, we stratified 
probands into lower (≤ 70) and higher IQ (> 70) cohorts (Figure 4.1c). Interestingly, while LGD 
mutations associated with lower IQs were strongly enriched only in prenatally biased exons 
(binomial one-tail test p = 6×10-3, RR = 1.62), mutations associated with higher IQs were 
exclusively enriched in postnatally biased exons (p = 0.05, RR = 1.27). These results 
demonstrate that mutations in exons with biases towards prenatal and postnatal expression 
preferentially contribute to ASD cases with lower and higher IQ phenotypes, respectively. We 
note that the observed exon developmental biases for LGD mutations are not simply driven by 
biases at the gene level, as mutations associated with both higher and lower IQ phenotypes 





Figure 4.1 Relationship between the developmental expression of exons and intellectual ASD 
phenotypes. (a) Exon developmental expression profiles for genes with de novo LGD mutations in SSC. 
Exons from all genes harboring LGD mutations were sorted into four groups (“strong prenatal bias”, 
“prenatal bias”, “no bias”, and “postnatal bias”) based on their overall developmental expression bias; 
the developmental bias was calculated as the log2 fold change between the average prenatal and postnatal 
exon expression levels. Lines represent the average expression profiles for exons in each group, and the x-
axis represents 12 periods of human brain development, based on data from the Allen Institute’s 
BrainSpan atlas [69]. The vertical dotted line delineates prenatal and postnatal developmental periods. 
Error bars represent the SEM. (b,c) Enrichment of LGD mutations across the four exon groups with 
different developmental biases. The y-axes represent the enrichment (relative rate) of mutations in each 
exon group; the enrichment was calculated by randomizing LGD mutations across exons proportionally 
to the exons’ coding sequence lengths (see Methods). Error bars represent the SEM. (b) The overall 
enrichment of LGD mutations across the four exon groups of exons with different developmental 
expression biases. (c) The enrichment of LGD mutations across the four exon groups calculated separately 




P = 8 × 10-3























































































































Figure 4.2 Relationship between the developmental expression profiles of ASD genes and IQ 
phenotypes. (a) Developmental expression profiles for genes harboring LGD mutations in SSC. Genes 
were grouped into four bins based on their developmental expression bias, i.e. the fold change between 
prenatal and postnatal expression. Lines represent the expression for genes in the four bins: genes with 
strong prenatal bias, genes with prenatal bias, genes with postnatal bias, and genes with strong postnatal 
bias. The x-axis represents different time periods across human brain development. The y-axis represents 
the relative expression of genes in each bin, defined as the average log2 fold-change relative to the mean 
expression level across all periods. Error bars represent the SEM. The vertical grey line delineates 
prenatal and postnatal developmental periods. (b,c) Enrichment of LGD mutations in genes across 
different bins (x-axis). The y-axes represent the enrichment of mutation in each group compared to the 
expected mutation frequency based on random shuffling of mutations across the full coding length of the 
corresponding protein. Error bars represent the SEM. (b) The enrichment of SSC LGD mutations in genes 
from the four bins. (c) The enrichment of SSC LGD mutations in the four bins for probands with higher 
(>70, red) and lower (<70, blue) nonverbal IQs. 
 
Cell type-specific expression biases in ASD-associated genes 
 To understand which cell types are likely to be affected by mutations in ASD, we 
analyzed the expression of ASD genes in multiple cell type expression datasets. Initially, we 
used an expanded set of genes [100] to identify cell types expressing ASD genes at high levels. 
Specifically, we calculated the cell type-specific expression bias, defined as the difference, in 
standard deviations, between expression levels in a cell compared to the average expression level 
across all other cells (see Methods). By applying the approach to a commonly used TRAP-seq 































































































































identified biased expression towards multiple cell types, including deep layer projection neurons 
in the cortex, inhibitory interneurons in the cortex, granule neurons in the cerebellum, and 
medium spiny neurons in the striatum (Figure 4.3). Importantly, these findings both confirmed 
and expanded on previous findings of ASD-associated cell types [5, 21, 103, 104]. 
 
Figure 4.3 Cell type-specific expression biases in TRAP-seq dataset. Each bar represents the 
expression bias of ASD-associated genes towards a cell type. The x-axis represents the expression bias 
towards each cell type, calculated as the difference between the median specificity of ASD genes and the 
median specificity of genes with nonsynonymous mutations in siblings (see Methods). Along the y-axis, 
cell types are ordered by decreasing bias significance. Colored bars represent statistically significant 
biases (BH FDR q £ 0.05), and empty bars represent biases that are not statistically significant. Error bars 
represent the SEM. 
 We also investigated the cell type expression biases in several single cell sequencing 
datasets. One such dataset, the Harvard Brain Cell Atlas [105], comprised ~690,000 cells 
collected from nine regions of the adult mouse brain. An analysis of 30 “metacell” clusters (i.e. 
broad cell types based on unsupervised clustering) characterized in the dataset confirmed biases 
towards neurons in the cortex (including pyramidal cells and inhibitory interneurons), striatum, 
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and hippocampus, as well as novel cell populations in the amygdala and thalamus (Figure 4.4). 
In an analysis of the Karolinka Institute’s Mouse Brain Atlas [103, 106], which measured 
expression in ~500,000 cells from 19 mouse brain regions and developmental periods, we 
identified novel biases towards hippocampal neurons, serotonergic neurons, and developing cell 
types including neuroblasts and embryonic neuronal populations (Figure 4.5). These results 
suggest that many cell types in diverse regions of the brain may be affected in ASD. 
 
Figure 4.4 Cell type-specific expression biases in the Harvard Brain Cell Atlas. Each bar 
represents the expression bias of ASD-associated genes towards a cell type. The x-axis represents the 
expression bias towards each cell type, calculated as the difference between the median specificity of ASD 
genes and the median specificity of genes with nonsynonymous mutations in siblings (see Methods). 
Dark colored bars represent statistically significant biases (BH FDR q £ 0.05), and light colored bars 
represent non-statistically significant biases. Error bars represent the SEM. 
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Figure 4.5 Cell type-specific expression biases in the Mouse Brain Atlas. Each bar represents the 
expression bias of ASD-associated genes towards a cell type. The x-axis represents the expression bias 
towards each cell type, calculated as the difference between the median specificity of ASD genes and the 
median specificity of genes with nonsynonymous mutations in siblings (see Methods). Dark colored bars 
represent statistically significant biases (BH FDR q £ 0.05), and light colored bars represent non-
statistically significant biases. Error bars represent the SEM. 
 We next investigated whether genes with different biological functions showed 
expression biases towards specific implicated cell types. To that end, we performed hierarchical 
cluster to identify functionally related ASD genes using a gene-gene interaction network [1, 5] 
(see Methods). Consistent with previous findings, we identified four functional clusters of genes: 
(1) chromatin modification genes, (2) transcription factors, (3) cytoskeletal and signaling genes, 
and (4) synaptic and ion-channel genes. Genes involved in chromatin modification and 
transcriptional regulation were, as expected, biased towards developing active neurons (Figure 
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4.6, blue). Interestingly, these developmentally active genes were also strongly biased towards 
differentiated cell types in the adult brain, i.e. striatal, cortical, and hippocampal neurons. 
Synaptic signaling and ion channel genes, on the other hand, were only biased towards adult 
neurons (Figure 4.6, red). 
 
Figure 4.6 Cell type-specific expression biases grouped by biological function. Each bar 
represents the expression bias of ASD-associated genes towards a cell type. The y-axes represent 
expression biases towards cell type (see Methods). Panels represent the biases observed for genes in the 
chromatin modification and transcript factor clusters (top) or in the synaptic, signaling, and ion channel 
clusters (bottom). Dark colored bars represent statistically significant biases (BH FDR q £ 0.05), and light 
colored bars represent biases that are not statistically significant. Error bars represent the SEM. 
 Interestingly, in addition to strong biases towards neurons, in general, and cortical 
neurons, specifically, ASD-associated genes also showed biased expression between Drd1+ (D1) 
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biases towards D2 MSNs versus D1 MSNs, defined as the log2 fold-change in expression, were 
an order of magnitude larger for ASD genes than for genes with similar expression levels in 
neurons; ASD mean bias = 0.12 versus expression-matched mean bias = 0.001; Wilcoxon rank-
sum on-tail test p = 1.3´10-7; statistical bootstrap p £ 1´10-4. We then calculated, the enrichment 
of D2 MSN-biased genes among ASD-associated genes. The analysis showed genes with 
stronger biases towards D2 MSNs were also more enriched in ASD (Figure 4.8). Notably, these 
expression biases between D2 and D1 MSNs, which have highly correlated gene expression 
levels, suggests that mutations in ASD may have different functional effects even between 
closely related cell types.  
 
Figure 4.7 Comparative expression biases for ASD-associated genes. In each analysis, we 
compared expression biases between different cell populations in the mouse brain. From left to right 
along the x-axis, we considered bias differentials between neurons and non-neurons, cortical neurons and 
non-cortical neurons, and between Drd2+ and Drd1+ medium spiny neurons (MSN). The y-axis 
represents the average difference in bias for autism genes, normalized by the average difference for all 
genes. Standard errors were estimated by statistical bootstrapping. The dotted line represents values for 































Figure 4.8 Enrichment of LGD mutations for genes with biased expression in MSNs. Genes were 
grouped by expression bias towards D2 versus D2 medium spiny neurons. Points represent the observed 
enrichment of bias-grouped genes among ASD-associated. The x-axis represents the minimum D2/D1 
bias for the considered genes. The y-axis represents the enrichment of genes among ASD genes, i.e. the 
fraction of genes in each bias-group for ASD-genes normalized by the expected fraction. Expected 
fractions were estimated by randomizing genes proportional to their coding sequence lengths. Error bars 
represent the SEM. 
 
Phenotypes associated with expression biases toward neuronal cell types 
 Given the diversity of cell types affected by ASD-associated mutations, we next 
investigated whether mutations in genes biased towards different implicated cell types would 
have different phenotypic consequences. To explore such relationships, we considered only 
ASD-associated genes harboring likely gene-disrupting (LGD) mutations, which are likely to 
have especially large phenotypic effects, in the Simons Simplex Collection (SSC) [8]. We then 
compared the phenotype scores for individuals affected by LGD mutations with the expression 
bias towards implicated cell types (see Methods). We found that expression biases towards 
cortical neurons were significantly associated with the severity of specific ASD phenotypes, 
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0.031, 0.009, 0.026; Figure 4.9, left). Similarly, mutations affecting genes with expression biases 
towards cerebellar projection neurons (i.e. Purkinje cells, granule cells, and deep cerebellar 
nuclei) were associated with decreases in fine motor skills and general coordination (MK p = 
0.015, 0.033; Figure 4.9, right). 
 
Figure 4.9 Association between cell type-specific expression and ASD phenotype severity. Each 
plot shows the severity of ASD phenotypes versus the specificity of genes towards specific cell types. 
Genes harboring LGD were grouped into four quartile bins based on their expression specificity towards 
(a) cortical neurons or (b) cerebellar projection neurons. The x-axes show the expression specificity 
quantiles for each bin. The y-axes show the standardized severity of (a) cognitive, adaptive, and social 
phenotypes or (b) fine motor skills and coordination phenotypes. Phenotypes were adjusted for age and 
gender, then normalized to z-scores (see Methods). Error bars represent the SEM. 
 
Combined effects of dosage changes and cell-type specificity 
 Importantly, our previous analyses of cell type-to-phenotype relationships did not 
account for either dosage changes due to LGD variants or the sensitivity of phenotypes to 
changes in dosage (PDS). Since both are important determinants of the severity of phenotypes 
(see Chapter 2), we decided to use our previously developed models to investigate the 
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analysis beyond individual scores and to reduce the number of hypotheses tested, we performed 
PCA-based dimensional reduction (see Methods) on an expanded dataset of 31 phenotype scores. 
The result of the procedure was three summary scores (“eigen-scores”), each a linear 
combination of multiple raw scores, with each summary score representing a different axis of 
autism phenotypes: (1) social and cognitive ability, (2) repetitive behaviors, and (3) motor skills. 
These scores were only weakly correlated (Spearman’s r = 0.26, 0.42, 0.24, for social-repetitive, 
social-motor, and repetitive-motor, respectively).  
 To analyze the aforementioned scores, we initially applied our previously developed 
PDS/dosage model, which accounts for phenotype severity due differences in effect on gene 
dosage across exons as well as phenotype sensitivity to dosage changes of different genes. 
Consistent with our previous findings, the normalized phenotypic effects for these aggregated 
phenotypes were strongly correlated with relative exon expression (social/repetitive/motor 
Pearson’s R = 0.61, 0.44, 0.65; Figure 4.10). Interestingly, by correlating the PDS values for 
phenotypes across genes, we observed that different phenotypes often had different sensitivities 
to changes in the dosage of the same gene (Spearman’s r = 0.22, 0.7, 0.45 for social-repetitive, 





Figure 4.10 Correlation between relative exon expression and normalized phenotypic effects. 
Each point represents a proband with an LGD mutations in SSC. The x-axis represents the relative 
expression of the target exon, i.e. the exon expression level divided by the gene expression level. The y-
axis represents the normalized effects of LGD mutations on aggregated (a) social and cognitive (b) 
repetitive and (c) motor skill phenotypes. Scores were normalized by the PDS values of target genes (see 
Methods). 
 Given that these models only explain part (~20-40%) of the phenotypic variance in ASD 
probands, we then considered whether the expression biases towards specific cell types could 
explain additional phenotypic variability not captured by PDS/dosage models. To investigate, we 
used our dosage models to normalize phenotypes, as described above. We then fitted a least-
squares linear regression between the relative exon expression and normalized phenotype scores, 
and used the residuals – i.e. the normalized variance unexplained by the model – as phenotype 
scores. Importantly, the procedure allowed us to investigate whether cell type-specific expression 
affects phenotypes after account for variance due to differences in gene dosage. 
Pearson's R = 0.61
p = 1.3×10-8
Pearson's R = 0.44
p = 1.1×10-4
















































































Figure 4.11 Residual phenotypic variance explained by pairwise cell type expression biases. 
Each point in scatterplots represents a proband affected by an LGD mutation in SSC. The x-axis 
represents the expression bias of the target gene. Biases were calculated as the fold-change between (a) 
Purkinje cells and other cerebellar cells or between (b) pyramidal cells in the posterior and anterior 
cortex. The y-axis represents the residual phenotype severity (i.e. severity after normalizing for gene 
dosage and PDS) for (a) motor skills or (b) social phenotypes. 
 To model the residual phenotypes, we calculated the rank correlations between cell type 
expression biases and the residual phenotype scores (Figure 4.11). As explanatory variables, we 
calculated pairwise biases in expression between related cell types. Specifically, we performed 
hierarchical clustering to identify related cell types. Then for each merge in the clustering tree, 
we calculated the gene expression biases (i.e. difference in specificity) between merged cell 
types. Interestingly, we found that differences in expression indeed explain a substantial fraction 
of the variance. The expression between Purkinje cells and granule cells in the cerebellum, for 
example, correlated strongly with residual motor phenotypes (Spearman’s r = 0.64, Benjamini-
Hochberg FDR q = 0.0005). We also found that expression biases towards the posterior cortex, 
versus anterior cortex, were inversely correlated with the residual severity of social phenotypes 












































































































populations correlate with phenotype severity, explaining ~40% and ~25% of the residual 
phenotypic variance. Importantly, these relationships are independent of the relationship between 
dosage and phenotypes. Cumulatively, these relatively simple models of phenotypes likely 




Enrichment of mutations in developmentally biased exons 
 To calculate the developmental expression biases, we used expression data from the 
BrainSpan expression atlas [69]. For the analysis, we used RNA-seq Gencode v10 summarized 
data, available online (http://brainspan.org/static/download.html). Expression values were log-
scaled and domain-shifted by a pseudocount (log2 x+1). Means were calculated across all 
prenatal or postnatal samples. Only exons expressed in the brain were considered (average 
RPKM ³1). The developmental expression bias was calculated as the log fold-change (i.e. the 
difference in log-scale) between the average prenatal and postnatal expression levels. 
To calculate enrichment in exon groups, all exons from genes harboring LGD mutations 
were partitioned into quartile groups based on developmental bias. Enrichments in each exon 
group were calculated by comparing the fraction of LGD mutations affecting the exons with 
fraction of coding sequence in the exons’ coding sequences (CDS). Coding sequence lengths 
were obtained from Gencode v10 annotations. Relative rates reported for developmentally biased 
exon groups were calculated by comparing the enrichment in the biased group to the enrichment 
observed for exons with no developmental bias. 
 
Cell-type specific expression biases 
 Single cell-type specific expression data was obtained from multiple ongoing projects. 
From the Karolinska Institute’s Mouse Brain Atlas, we analyzed single-cell expression data 
~500,000 cells from 19 regions of the developing and adult mouse brain [106]. Specifically, we 
downloaded a commonly used prepared dataset summarized expression to 24 cell type clusters 
avalailable online (http://mousebrain.org/downloads.html). From the Harvard Brain Cell Atlas, 
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we obtained data for ~690,000 cells from nine regions of the adult mouse brain, which had been 
clustered into 30 broad cell-type classes (aggregated metacell dataset; http://dropviz.org/) [107]. 
Finally, we applied our developed methods to a previously analyzed dataset of 24 cell types with 
expression levels characterized using TRAP-seq [101, 102]. To analyze ASD genes using cell 
type expression datasets from the mouse brain, we mapped human genes onto mouse orthologs 
using the NCBI Homologene database [108]. 
To analyze the aforementioned datasets, we calculated the specificity of genes towards 
each cell type. Specifically, for each cell type, we defined the specificity bias of expression as 





Where 𝑧N represents the expression specificity towards cell type c, 𝑥N represents the expression 
level of the gene in that cell type, 𝜇O represents the average expression across all cell types, and 
𝜎O represents the standard deviation of expression across all cells. The reported ASD bias 
statistics for each cell type were calculated as the difference between median specificity for 
ASD-associated genes and median specificity for genes with nonsynonymous mutations in 
unaffected siblings (?̃?PQR − ?̃?1IA>I$?). Significance was tested using a Mann-Whitney U one-tail 
test and adjusted for multiple hypotheses with a Benjamini-Hochberg FDR correction. 
 
Grouping ASD-associated genes by biological function 
 To group ASD-associated genes by biological function, we adapted a method developed 
in our previous work. Specifically, we used a gene-gene interaction network (i.e. NETBAG+), 
where edged between genes represented the probability of genes contributing to similar 
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biological function. We used an updated version of the network (available by request) to perform 
the clustering. 
 Using the gene-gene interaction network, we calculated the similarity between genes as 
the Spearman rank correlation between interactions across all other genes in the network. We 
converted similarity measures to distance measures by calculating 1-r, where r represents the 
calculated rank correlation. We then used agglomerative hierarchical clustering with Ward’s 
linkage criterion to group genes. Based on previous findings, we divided genes into four clusters, 
namely chromatin modification, transcription factors, cytoskeleton and signaling, and synaptic 
genes. We then analyzed cell-type specific biases for each functional cluster of genes. 
 
Figure 4.12 Radial dendrogram of functional clusters of ASD genes. ASD-associated genes were 
hierarchically clustered based on pairwise similarity (1-correlation) of edge weights on a gene-gene 
interaction network (see Methods). Clustering was done using Ward’s linkage criterion. Gene labels were 














































































































































































































































































































































































































































































Standardization of ASD phenotypes 
In the analyses of autism phenotype scores, we considered SSC probands, notably of 
different genders and spanning a broad range of ages. To account for developmental differences 
across age and gender, for each phenotype statistically significantly (FDR £ 0.05) correlated with 
age or gender, we adjusted phenotypic scores to account for these variables. We used a binary 
variable (taking value 0 for male or 1 for female) to estimate significant mean differences across 
genders. Following a previously developed approach [97], we adjusted scores using linear 
regression. Specifically, we performed a multivariate linear regression for each phenotypic score, 
with age and/or gender as independent regression parameters. We then used the regression 
residuals as adjusted scores for comparing proband phenotypes. We approximated probands’ 
ages as the age at which Autism Diagnostic Observation Schedule was administered (i.e. “age at 
ADOS”). 
After regression, we standardized scores to phenotypic z-scores, defined as the 
difference, in standard deviations, between a given proband’s phenotype score and the average 
score across all probands. The procedure centered and scaled phenotypic scores for combined 
analysis of multiple phenotypes. 
 
Calculation of aggregated phenotype scores 
 To study the effects across a larger set of phenotype scores, we performed dimensional 
reduction to summarize phenotypes. Specifically, we used a defined list of scores available in 
SSC, which were curated by SSC clinicians to capture important phenotypic features of autism 
(“Core Descriptive Variables” in the Phenotype Data Dictionary). These scores were further 
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grouped into several phenotype categories, with groups of scores quantifying adaptive/cognitive, 
language/communication, social, and repetitive behaviors. We used SSC Version 15, Phenotype 
Data Set 9, available on SFARI Base. 
 For each group of core descriptive variables, we performed Principal Component 
Analysis (PCA), after centering and scaling variables. We then considered the first principle 
component (PC), i.e. the linear combination of scores explaining the most inter-individual 
variance for all scores in the group, and used it as a summary score for the represented behavior. 
Importantly, for each group, these principal components explained a majority of the total 
variance (~45-80%, Figure 4.13) suggesting that our method effectively captures the phenotypic 
variation in common between all scores. Component directions were chosen so that higher scores 
represent more severe phenotypes. 
 
Figure 4.13 Variance explained by eigenphenotypes. Principal components were calculated for 
each set of curated phenotypes in SSC. From left to right, the x-axis represents social, language, repetitive, 
cognitive, and motor skill phenotype scores. The y-axis represents the variance explained by either the 
first principal component (colored bars) or cumulatively by both the first and second principal 








































 Although our approach reduced the dimensionality of the phenotype dataset, it did not 
guarantee either independence or zero correlations between phenotypes. Consequently, we 
calculated the correlations between all pairs of scores (Figure 4.14). Based on the analysis, we 
further grouped the social, language, and cognitive phenotype groups. We then performed PCA 
to obtain a summary score for the combined group of scores. 
 
Figure 4.14 Correlation between aggregated phenotypes. In the upper triangle of the grid: Each 
point in the scatterplots represents a proband in SSC. The x-axes represent scores for the aggregated 
phenotype in the text label below the scatterplot. The y-axes represent scores for the aggregated 
phenotype labeled to the right of the scatterplot. Red lines represent spline regressions between variables. 
In the lower triangle of the grid: Each box represents the Pearson (rp) or Spearman (rs) correlation, 
calculated across all probands, between aggregated phenotype scores. For each box, the correlated 
phenotypes are labeled along the diagonal to the left and above. The size of correlation coefficients is 
proportional to the strength of the correlation. 
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Previous studies explored phenotypic similarity in syndromic forms of ASD due to 
mutations in specific genes [51, 54, 56, 109, 110]. Nevertheless, across a large collection of 
contributing genes, the nature of the substantial phenotypic heterogeneity in ASD is not well 
understood. Interestingly, the diversity of intellectual and other important ASD phenotypes 
resulting from de novo LGD mutations in the same genes is usually only slightly (~10%) smaller 
than the phenotypic diversity across the entire ASD cohort. The presented studies explored 
multiple biological mechanisms contributing to phenotypic heterogeneity in simplex ASD cases 
triggered by LGD mutations. 
Truncating mutations, even in the same gene, can have different NMD-mediated effects 
on gene dosage. Heterozygous truncating genotypes on average decrease gene expression by 
~15-30%, but effect sizes vary across several orders of magnitude. Such differences in the 
dosage effects of truncating mutations likely contribute to the phenotypic variability across 
probands. In addition to effects associated with different changes in gene dosage, there is also 
substantial variability in the sensitivity of a phenotype to changes in the dosage of specific genes. 
When dosage-sensitivities are taken into account (for example, using gene-specific PDS values), 
predicted dosage changes correlate strongly with the severity of phenotypes (R2 ~ 0.4). These 
quantitative relationship between changes in dosage and phenotype are likely to specific 
phenotype-gene pairs.  
 Perturbations leading to similar dosage changes in the same gene may affect different, 
functionally distinct splicing isoforms. However, when exactly the same sets of isoforms are 
perturbed, as for LGD mutations in the same exon, the resulting phenotypes, even in unrelated 
ASD probands, are especially similar. For LGD mutations affecting intellectual phenotypes, we 
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found that same exon membership accounts for a larger fraction of phenotypic variance than 
multiple other genomic features, including expression, evolutionary conservation, pathway 
membership, and domain truncation. There are likely deviations from these patterns for specific 
genes and specific mutations. For example, truncated proteins that escape NMD may lead to 
partial buffering, due to remaining activity, or to further damaging effects, due to dominant 
negative interactions. Nevertheless, our results suggest that for de novo LGD mutations in ASD, 
exons, rather than genes, often represent a unit of effective phenotypic impact. 
The dosage models developed in the present work can likely be applied in other contexts. 
While we studied dosage changes due to NMD of truncating variants, other mechanisms of 
dosage change, such as regulatory mutations, may also be used to characterize dosage-trait 
relationships. As genetic and phenotypic data accumulate, it will be interesting to estimate the 
sensitivity of multiple phenotypes for a substantial number of ASD risk genes. Furthermore, 
given the consistent patterns of gene and isoform-specific dosage effects across tissues, it may be 
possible to estimate sensitivity parameters (i.e. PDS) for other genetic disorders and phenotypes. 
In this respect, quantitative gene-dosage relationships have been recently characterized for yeast 
fitness values in different environmental conditions [111]. 
The present study focused specifically on simplex cases of ASD, in which de novo LGD 
mutations are highly penetrant and where the contribution of genetic background is minimized. It 
is likely that differences in genetic background and environment represent other important 
sources of phenotypic variability [22, 61, 112]. Therefore, in more diverse cohorts, individuals 
with LGD mutations in the same exon will likely display greater phenotypic heterogeneity. For 
example, the Simons Variation in Individuals Project has identified broad spectra of phenotypes 
associated with specific variants in more general populations [29, 113-115]. Similarly, probands 
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from trio families (i.e. with no unaffected siblings) show greater variability in phenotypes. For 
these probands, the enrichment of de novo LGD mutations is substantially lower and the 
contribution from genetic background is likely to be larger [34], resulting in more pronounced 
phenotypic variability. 
Our study may have important implications for precision medicine [112, 116, 117]. The 
presented results indicate that relatively mild decreases in gene dosage may account for a 
substantial fraction of adverse phenotypic consequences. Thus, from a therapeutic perspective, 
compensatory expression of intact alleles, as demonstrated in mouse models of ASD [118-120] 
and other diseases [121], may provide an approach for alleviating phenotypic effects for at least a 
fraction of ASD cases. From a prognostic perspective, our results suggest that by sequencing and 
phenotyping sufficiently large patient cohorts with truncating mutations in different exons, it 
may be possible to understand likely phenotypic consequences originating from LGD mutations 
in specific exons. Furthermore, because we observed consistent patterns of expression changes 
across multiple human tissues, similar analyses may be also extended to other disorders affected 
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